inositol has been researched along with Diabetes Mellitus, Adult-Onset in 191 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adding mitiglinide/voglibose to vildagliptin therapy results in more efficient postprandial glucose control and less hypoglycemia than adding glimepiride." | 9.27 | Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial. ( Fujimoto, K; Hamamoto, Y; Hamasaki, A; Honjo, S; Shibayama, Y; Yamaguchi, E, 2018) |
| "To assess the therapeutic effect of losartan on type 2 diabetes mellitus (DM2) with gas chromatography (GC)-based metabonomics." | 7.74 | [Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics]. ( Gao, P; Lu, X; Shi, XZ; Xu, GW; Yuan, KL, 2007) |
| "D-chiro-inositol (DCI) is a drug candidate for the treatment of type 2 diabetes and polycystic ovary syndrome, since it improves the efficiency with which the body uses insulin and also promotes ovulation." | 7.73 | Genetic modification of Bacillus subtilis for production of D-chiro-inositol, an investigational drug candidate for treatment of type 2 diabetes and polycystic ovary syndrome. ( Ashida, H; Ikeuchi, M; Kinehara, M; Morinaga, T; Yamaguchi, M; Yoshida, K, 2006) |
| " We quantified urinary chiro-inositol excretion using gas chromatography-mass spectrometry and the insulin sensitivity index (SI), and glucose effectiveness (SG) using Bergman's modified minimal model method." | 7.69 | Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes. ( Hinokio, Y; Hirai, A; Hirai, M; Hirai, S; Kawasaki, H; Matsumoto, M; Ohtomo, M; Onoda, M; Satoh, Y; Suzuki, S, 1994) |
| "Inositol is a polyalcohol, naturally occurring as nine stereoisomers, including D-chiro-inositol (DCI) and myo-inositol (MI), which have prominent roles in the metabolism of glucose and free fatty acids." | 6.53 | Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives. ( Brady, DM; Laganà, AS; Maniglio, P; Paul, C; Triolo, O, 2016) |
| "Evidence from seven studies shows that antenatal dietary supplementation with myo-inositol during pregnancy may reduce the incidence of gestational diabetes, hypertensive disorders of pregnancy and preterm birth." | 5.41 | Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes. ( Alsweiler, J; Crawford, TJ; Crowther, CA; Lin, L; Motuhifonua, SK, 2023) |
| "As in humans, monkeys with NIDDM have a lower urinary excretion rate of chiroinositol (CI), a component of a putative mediator of insulin action, compared to normal monkeys." | 5.29 | Chiroinositol deficiency and insulin resistance. I. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys. ( Bodkin, NL; Hansen, BC; Larner, J; Lilley, K; Ortmeyer, HK, 1993) |
| "Adding mitiglinide/voglibose to vildagliptin therapy results in more efficient postprandial glucose control and less hypoglycemia than adding glimepiride." | 5.27 | Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial. ( Fujimoto, K; Hamamoto, Y; Hamasaki, A; Honjo, S; Shibayama, Y; Yamaguchi, E, 2018) |
| "Linagliptin modestly improves glycemic profile in patients with well controlled T2DM; however, it may not have an effect on insulin sensitivity in these patients." | 5.27 | Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial. ( Bhansali, A; Bhansali, S; Bhat, K; Kurpad, AV; Parthan, G; Walia, R, 2018) |
| " We conclude that plasma levels of both pinitol and D-chiro-inositol are very responsive to pinitol ingestion, but insulin sensitivity does not increase after pinitol treatment in individuals with obesity and mild type 2 diabetes." | 5.09 | Effect of pinitol treatment on insulin action in subjects with insulin resistance. ( Christiansen, M; Davis, A; Hellerstein, MK; Horowitz, JF; Klein, S; Ostlund, RE, 2000) |
| "Inositol supplementation decreases blood glucose through an improvement in insulin sensitivity that is independent of weight." | 5.01 | Effects of inositol on glucose homeostasis: Systematic review and meta-analysis of randomized controlled trials. ( Corcoy, R; Cuixart, G; Gonçalves, A; Miñambres, I, 2019) |
| "Myo-inositol treatment in early pregnancy is associated with a reduction in the rate of gestational diabetes mellitus and in the risk of preterm birth and macrosomia in women who are at risk for gestational diabetes mellitus." | 3.88 | Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. ( Alibrandi, A; Corrado, F; D'Anna, R; Di Benedetto, A; Facchinetti, F; Pintaudi, B; Santamaria, A, 2018) |
| " Body weight, blood glucose, glycated haemoglobin, insulin, serum leptin, HOMA-insulin resistance scores, intestinal amylase activity, serum and faecal lipids and food and fluid consumption were measured." | 3.83 | The effect of combined inositol hexakisphosphate and inositol supplement in streptozotocin-induced type 2 diabetic rats. ( Bustamante, J; Dilworth, LL; Foster, SR; Lindo, RL; Omoruyi, FO, 2016) |
| "We previously reported that a chronic supplementation with myo-inositol (MI) improved insulin sensitivity and reduced fat accretion in mice." | 3.81 | Abnormalities in myo-inositol metabolism associated with type 2 diabetes in mice fed a high-fat diet: benefits of a dietary myo-inositol supplementation. ( Croze, ML; Géloën, A; Soulage, CO, 2015) |
| "To assess the therapeutic effect of losartan on type 2 diabetes mellitus (DM2) with gas chromatography (GC)-based metabonomics." | 3.74 | [Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics]. ( Gao, P; Lu, X; Shi, XZ; Xu, GW; Yuan, KL, 2007) |
| "D-chiro-inositol (DCI) is a drug candidate for the treatment of type 2 diabetes and polycystic ovary syndrome, since it improves the efficiency with which the body uses insulin and also promotes ovulation." | 3.73 | Genetic modification of Bacillus subtilis for production of D-chiro-inositol, an investigational drug candidate for treatment of type 2 diabetes and polycystic ovary syndrome. ( Ashida, H; Ikeuchi, M; Kinehara, M; Morinaga, T; Yamaguchi, M; Yoshida, K, 2006) |
| " We quantified urinary chiro-inositol excretion using gas chromatography-mass spectrometry and the insulin sensitivity index (SI), and glucose effectiveness (SG) using Bergman's modified minimal model method." | 3.69 | Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes. ( Hinokio, Y; Hirai, A; Hirai, M; Hirai, S; Kawasaki, H; Matsumoto, M; Ohtomo, M; Onoda, M; Satoh, Y; Suzuki, S, 1994) |
| "Patients with type 2 diabetes who were admitted to our hospital were enrolled in our study (n = 12)." | 2.94 | Comparison of the Efficacy of Repaglinide Versus the Combination of Mitiglinide and Voglibose on Glycemic Variability in Japanese Patients with Type 2 Diabetes. ( Fukui, M; Hasegawa, G; Hirata, A; Kadono, M; Nakajima, H; Okada, H; Okada, Y; Oyamada, H; Tanaka, M; Yamane, T, 2020) |
| "Vogmet is a safe antihyperglycemic agent that controls blood glucose level effectively, yields weight loss, and is superior to metformin in terms of various key glycemic parameters without increasing the risk of hypoglycemia." | 2.90 | Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial. ( Baik, SH; Cha, BS; Choi, SH; Jeong, IK; Kim, DM; Kim, IJ; Kim, SR; Kim, YS; Lee, IK; Lee, KW; Lee, MK; Min, KW; Oh, TJ; Park, JH; Park, JY; Park, SW; Park, TS; Son, HS; Song, YD; Yoon, KH; Yu, JM, 2019) |
| "Patients with type 2 diabetes mellitus (T2DM) have a higher incidence of cardiovascular (CV) events." | 2.87 | Effects of a Carob-Pod-Derived Sweetener on Glucose Metabolism. ( Badimon, L; Cubedo, J; Hernández-Mijares, A; Lambert, C; López-Bernal, S; Padró, T; Rocha, M; Vilahur, G, 2018) |
| "MATERIAL AND METHODS Five patients with type 2 diabetes were enrolled and treated with insulin degludec and metformin as a basal therapy." | 2.84 | Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus. ( Ihana-Sugiyama, N; Kakei, M; Noda, M; Sugiyama, T; Tsujimoto, T; Yamamoto-Honda, R, 2017) |
| "Sitagliptin or voglibose combined with SAP can improve glucose control and protect islet function for patients with newly diagnosed T2DM." | 2.82 | [Comparison of therapeutic effects between sitagliptin and voglibose both combined with sensor-augmented insulin pump in newly diagnosed type 2 diabetes]. ( Bai, R; Du, JL; Liu, D; Shi, CH; Wang, H; Wang, L; Wang, YB; Yang, Y; Zhang, XY, 2016) |
| "Patients with type 2 diabetes who were inadequately controlled on twice-daily premixed insulin were randomly assigned (1:1) to receive either insulin lispro mix (mix 50 before breakfast and lunch plus mix 25 before dinner) or basal-bolus therapy (insulin glargine at bedtime plus prandial insulin lispro thrice-daily) for 24 weeks." | 2.80 | Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily pre ( Ahn, KJ; Bao, Y; Chen, L; Chuang, LM; Gao, F; Ji, Q; Jia, W; Li, P; Pang, C; Tu, Y; Xiao, X; Yang, J, 2015) |
| " The prevalence of adverse events and the risk of hypoglycemia were similar for both groups." | 2.80 | A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes. ( Baik, SH; Cha, BS; Jang, HC; Lee, IK; Lee, KW; Park, TS; Son, JW; Sung, YA; Woo, JT; Yoo, SJ; Yoon, KH, 2015) |
| "Teneligliptin is a novel DPP-4 inhibitor in development for treating type 2 diabetes mellitus that does not require dose adjustment for diabetic patients with end-stage renal disease; however, it had not been known whether or not teneligliptin is safe or potent in dialysis patients." | 2.79 | Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes. ( Kosaka, T; Kuwahara, Y; Nakamura, K; Otsuki, H; Shimomura, F; Tsukamoto, T, 2014) |
| "Betaine deficiency is a probable cardiovascular risk factor and a cause of elevated homocysteine." | 2.79 | Extreme urinary betaine losses in type 2 diabetes combined with bezafibrate treatment are associated with losses of dimethylglycine and choline but not with increased losses of other osmolytes. ( Chambers, ST; Elmslie, JL; George, PM; Krebs, JD; Lever, M; Lunt, H; McEntyre, CJ; Parry-Strong, A; Slow, S, 2014) |
| "We enrolled 47 Japanese patients with type 2 diabetes, with HbA1c levels with 7." | 2.79 | Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients. ( Fuchigami, M; Goda, T; Hariya, N; Inoue, S; Mochizuki, K; Osonoi, T; Saito, M, 2014) |
| "To assess the extent of pharmacokinetic and pharmacodynamic interaction between vildagliptin, a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-4) enzyme, and voglibose, an α-glucosidase inhibitor widely prescribed in Japan, when coadministered in Japanese patients with Type 2 diabetes." | 2.78 | Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes. ( Furihata, K; He, YL; Kulmatycki, K; Mita, S; Saji, T; Sekiguchi, K; Yamaguchi, M, 2013) |
| "Body weight was not clinically altered in either group." | 2.78 | Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes. ( Araki, E; Dugi, K; Hayashi, N; Horie, Y; Inagaki, N; Kawamori, R; Sarashina, A; Thiemann, S; von Eynatten, M; Watada, H; Woerle, HJ, 2013) |
| " Drug-related adverse event rates were comparable across treatment groups over 12 weeks (9." | 2.77 | Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. ( Araki, E; Dugi, KA; Gong, Y; Hayashi, N; Horie, Y; Inagaki, N; Kawamori, R; Sarashina, A; von Eynatten, M; Watada, H; Woerle, HJ, 2012) |
| "A total of 66 patients with type 2 diabetes who had been taking oral hypoglycemic agents for at least 3 months were enrolled and randomized to receive pinitol (n = 33) or matching placebo (n = 33)." | 2.77 | Effects of pinitol on glycemic control, insulin resistance and adipocytokine levels in patients with type 2 diabetes mellitus. ( Han, KA; Kim, HJ; Kim, YK; Ku, BJ; Lee, SK; Min, KW; Park, KS, 2012) |
| "In Japanese patients with type 2 diabetes, once-daily sitagliptin monotherapy showed greater efficacy and better tolerability than thrice-daily voglibose over 12 weeks." | 2.75 | Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. ( Amatruda, JM; Arjona Ferreira, JC; Iwamoto, Y; Kadowaki, T; Nishii, M; Nonaka, K; Tajima, N; Taniguchi, T, 2010) |
| " Overall adverse events (AEs) were lower in the vildagliptin-treated patients compared with that in the voglibose-treated patients (61." | 2.75 | Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. ( Iwamoto, Y; Kashiwagi, A; Mimori, N; Suzuki, M; Tachibana, H; Terao, S; Yamada, N, 2010) |
| "The increased prevalence of type 2 diabetes mellitus is a major concern for health providers." | 2.74 | Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. ( Iwamoto, Y; Kaku, K; Kashiwagi, A; Kawamori, R; Shimamoto, K; Tajima, N, 2009) |
| " No serious adverse effects such as hypoglycemia, liver impairment or rhabdomyolysis were observed in any of the patients." | 2.73 | Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis. ( Abe, M; Kaizu, K; Kikuchi, F; Matsumoto, K, 2007) |
| "In pioglitazone-treated patients, circulating adiponectin levels were significantly increased from 4 weeks after the start of treatment, and until the end of the study at 12 weeks." | 2.72 | Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study. ( Mori, M; Oh-I, S; Ohtani, KI; Okada, S; Shimizu, H; Tsuchiya, T, 2006) |
| "Postprandial hyperglycemia and hyperlipidemia are considered risk factors for cardiovascular disease." | 2.72 | An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. ( Aizawa-Abe, M; Kuzuya, H; Ogawa, Y; Satoh, N; Shimatsu, A; Suganami, T; Yamada, K, 2006) |
| "An open-label prospective cross-over trial was performed to compare the efficacy and adverse effects of nateglinide with those of voglibose on Japanese early type 2 diabetes (who were oral hypoglycemic agent naïve and whose HbA(1C) levels were between 7." | 2.72 | Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study. ( Hirose, T; Kawamori, R; Kawasumi, M; Kurebayashi, S; Tanaka, Y; Watada, H, 2006) |
| "Forty-five normotensive type 2 diabetes patients with microalbuminuria were randomized to 12-month treatment with pioglitazone (30 mg/d, n = 15), glibenclamide (5 mg/d, n = 15), or voglibose (0." | 2.71 | Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. ( Kawagoe, Y; Koide, H; Matsuda, T; Nakamura, T; Ogawa, H; Sekizuka, K; Takahashi, Y, 2004) |
| " Adverse drug events were more commonly reported in acarbose-treated patients (P<0." | 2.70 | Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. ( Ploybutr, S; Tunlakit, M; Vichayanrat, A; Watanakejorn, P, 2002) |
| "Sixteen NIDDM patients (4 patients treated with diet therapy alone and 12 receiving a sulfonylurea) were given 0." | 2.68 | Relationship between gastric emptying and an alpha-glucosidase inhibitor effect on postprandial hyperglycemia in NIDDM patients. ( Emoto, M; Inaba, M; Ishimura, E; Kawagishi, T; Morii, H; Nishizawa, Y; Okuno, Y; Tanaka, S; Taniwaki, H, 1997) |
| "Sorbinil treatment reduced the elevated sorbitol levels in the diabetic patients to normal or slightly below normal, but did not affect the erythrocyte myo-inositol concentration." | 2.65 | myo-Inositol and sorbitol in erythrocytes from diabetic patients before and after sorbinil treatment. ( Lomecky-Janousek, MZ; Popp-Snijders, C; Schouten, JA; van der Veen, EA, 1984) |
| "Inositol is a polyalcohol, naturally occurring as nine stereoisomers, including D-chiro-inositol (DCI) and myo-inositol (MI), which have prominent roles in the metabolism of glucose and free fatty acids." | 2.53 | Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives. ( Brady, DM; Laganà, AS; Maniglio, P; Paul, C; Triolo, O, 2016) |
| "People who develop type 2 diabetes pass through a phase of impaired glucose tolerance (IGT)." | 2.42 | Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? ( Scheen, AJ, 2003) |
| "Postprandial hyperglycemia is frequently associated with visceral obesity which plays a key role in metabolic abnormalities such as dyslipidemia and hypertension." | 2.42 | [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus]. ( Yamada, K, 2003) |
| "The eruptive xanthoma lesions gradually diminished in size and number and eventually disappeared by 12 months." | 1.51 | Eruptive xanthomas in a patient with soft-drink diabetic ketosis and apolipoprotein E4/2. ( Aiba, S; Imai, J; Katagiri, H; Kikuchi, K; Kohata, M; Kurosawa, S; Nakajima, T; Satake, C; Sawada, S; Takahashi, K; Takeda, K; Tsuchiya, S, 2019) |
| "LV functional parameters and the reactive hyperemia index also remained unchanged after the 24-week treatment." | 1.48 | Effect of Sitagliptin on Coronary Flow Reserve Assessed by Magnetic Resonance Imaging in Type 2 Diabetic Patients With Coronary Artery Disease. ( Dohi, K; Fujimoto, N; Ishida, M; Ito, M; Kumagai, N; Masuda, J; Moriwaki, K; Nakamori, S; Nakamura, M; Sakuma, H; Sato, Y; Sawai, T; Takeuchi, T; Yamada, N, 2018) |
| " Hence, dosage adjustment is not warranted in the use of AGIs in T2DM patients in situations of comorbidity." | 1.48 | Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus. ( Babu, RJ; Dash, RP; Srinivas, NR, 2018) |
| "Type 2 diabetes was induced in three groups using high-fat diet combined with a single dose of streptozotocin (35mg/kg body weight, intraperitoneally)." | 1.46 | Pancreatic and renal function in streptozotocin-induced type 2 diabetic rats administered combined inositol hexakisphosphate and inositol supplement. ( Alexander-Lindo, RL; Dilworth, LL; Foster, SR; Omoruyi, FO; Thompson, R, 2017) |
| "In this investigation, a model of type 2 diabetes mellitus (T2DM) was used on Sprague-Dawley (SD) rats to clarify more details of the mechanism in the therapy of T2DM." | 1.43 | Hypoglycemic effect of D-chiro-inositol in type 2 diabetes mellitus rats through the PI3K/Akt signaling pathway. ( Ai, RD; Gao, YF; Wang, TX; Wu, TC; Zhang, MN; Zhang, ZS, 2016) |
| "Many patients with type 2 diabetes mellitus(T2DM) do not achieve satisfactory glycemic control by monotherapy alone, and often require multiple oral hypoglycemic agents (OHAs)." | 1.42 | [Fixed-dose combination]. ( Nagai, Y, 2015) |
| "In this investigation, a model of type 2 diabetes mellitus (T2DM) with insulin resistance was established by feeding a high-fat diet (HFD) and injecting streptozocin (STZ) to Sprague-Dawley (SD) rats, targeting the exploration of more details of the mechanism in the therapy of T2DM." | 1.42 | Effects of D-Pinitol on Insulin Resistance through the PI3K/Akt Signaling Pathway in Type 2 Diabetes Mellitus Rats. ( Cai, H; Gao, Y; Wu, T; Xu, M; Zhang, M; Zhang, Z, 2015) |
| "The effects of the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, alone and in combination with voglibose or exendin-4, on glycaemic control and body weight were assessed in an animal model of type 2 diabetes." | 1.40 | Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats. ( Cheetham, SC; Headland, KR; Jones, RB; Klein, T; Mark, M; Vickers, SP, 2014) |
| "The combination significantly reduced postprandial hyperglycemia after each meal." | 1.40 | The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus. ( Cho, KY; Nakamura, A; Nomoto, H; Ono, Y, 2014) |
| "Seventeen type 2 diabetes patients were given sitagliptin 50 mg/day or voglibose 0." | 1.39 | Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study. ( Ando, K; Morimoto, A; Nishimura, R; Sakamoto, M; Seo, C; Tsujino, D; Utsunomiya, K, 2013) |
| "Type 2 diabetes is characterized by oxidative stress and a chronic low-grade inflammatory state, which also play roles in the pathogenesis of this disease and the accompanying vascular complications by increasing the production of free radicals and pro-inflammatory cytokines." | 1.38 | Antioxidant and anti-inflammatory effects of a hypoglycemic fraction from Cucurbita ficifolia Bouché in streptozotocin-induced diabetes mice. ( Alarcon-Aguilar, FJ; Almanza-Perez, JC; Angeles-Mejia, S; Banderas-Dorantes, TR; Blancas-Flores, G; Diaz-Flores, M; Fortis-Barrera, A; Gomez, J; Jasso, I; Roman-Ramos, R; Zamilpa-Alvarez, A, 2012) |
| "Twenty-one Japanese patients with type 2 diabetes were enrolled in this study." | 1.35 | Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. ( Domeki, N; Ikeda, S; Kasai, K; Kawagoe, Y; Matsumura, M; Miyashita, Y; Monden, T; Nakatani, Y; Shimizu, H; Yanagi, K, 2009) |
| "Patients with type 2 diabetes and major depression (n=20) were scanned along with patients with diabetes alone (n=24) and healthy controls (n=21) on a 1." | 1.34 | Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy. ( Ajilore, O; Binesh, N; Darwin, C; Haroon, E; Kumar, A; Kumaran, S; Miller, J; Mintz, J; Thomas, MA, 2007) |
| "Fifteen Korean subjects with type 2 diabetes mellitus (seven men, eight women; 60." | 1.33 | Pinitol from soybeans reduces postprandial blood glucose in patients with type 2 diabetes mellitus. ( Cha, IJ; Kang, MJ; Kim, JC; Kim, JI; Yoon, SY, 2006) |
| "A total of 21 inpatients with type 2 diabetes were recruited to a single-center, 2-period, crossover trial." | 1.33 | Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms. ( Fujisawa, T; Ikegami, H; Inoue, K; Kawabata, Y; Ogihara, T, 2005) |
| "Myo-inositol was even more elevated in patients with polyneuropathy (p = 0." | 1.32 | Alterations of cerebral metabolism in patients with diabetes mellitus studied by proton magnetic resonance spectroscopy. ( Feuerbach, S; Fründ, R; Geissler, A; Schölmerich, J; Zietz, B, 2003) |
| "However, the association between type 2 diabetes and oxidative stress in the pancreatic beta-cells has not been previously described." | 1.30 | Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. ( Hiai, H; Ihara, Y; Ikeda, H; Odaka, H; Seino, Y; Tanaka, T; Toyokuni, S; Uchida, K; Yamada, Y, 1999) |
| "Myoinositol influx was significantly but negatively correlated with the serum very low density lipoprotein (VLDL) cholesterol concentration in patients with and without neuropathy but not in the controls." | 1.29 | Relationship between myoinositol influx and lipids in diabetic neuropathy. ( Bomford, J; Ng, LL; Simmons, D, 1993) |
| "As in humans, monkeys with NIDDM have a lower urinary excretion rate of chiroinositol (CI), a component of a putative mediator of insulin action, compared to normal monkeys." | 1.29 | Chiroinositol deficiency and insulin resistance. I. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys. ( Bodkin, NL; Hansen, BC; Larner, J; Lilley, K; Ortmeyer, HK, 1993) |
| "Inositol is a major component of the intracellular mediators of insulin action." | 1.28 | Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. ( Bogardus, C; Craig, J; Hansen, BC; Hill, CR; Kennington, AS; Larner, J; Ortmeyer, HK; Raz, I; Romero, G, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (2.09) | 18.7374 |
| 1990's | 30 (15.71) | 18.2507 |
| 2000's | 57 (29.84) | 29.6817 |
| 2010's | 85 (44.50) | 24.3611 |
| 2020's | 15 (7.85) | 2.80 |
| Authors | Studies |
|---|---|
| Ibrahim, I | 1 |
| Abdullahi, H | 1 |
| Fagier, Y | 1 |
| Ortashi, O | 1 |
| Terrangera, A | 1 |
| Okunoye, G | 1 |
| Ramp, P | 2 |
| Pfleger, C | 1 |
| Dittrich, J | 1 |
| Mack, C | 2 |
| Gohlke, H | 1 |
| Bott, M | 2 |
| Ejiri, K | 2 |
| Miyoshi, T | 4 |
| Kihara, H | 4 |
| Hata, Y | 2 |
| Nagano, T | 2 |
| Takaishi, A | 2 |
| Toda, H | 2 |
| Namba, S | 1 |
| Nakamura, Y | 3 |
| Akagi, S | 3 |
| Sakuragi, S | 2 |
| Minagawa, T | 2 |
| Kawai, Y | 2 |
| Nishii, N | 2 |
| Fuke, S | 2 |
| Yoshikawa, M | 2 |
| Nakamura, K | 5 |
| Ito, H | 4 |
| Fu, Y | 1 |
| Ji, W | 1 |
| Liu, Q | 1 |
| Zhang, L | 1 |
| Li, C | 1 |
| Huan, Y | 1 |
| Lei, L | 2 |
| Gao, X | 1 |
| Chen, L | 2 |
| Feng, C | 1 |
| Zhai, J | 1 |
| Li, P | 2 |
| Cao, H | 1 |
| Liu, S | 1 |
| Shen, Z | 1 |
| Motuhifonua, SK | 1 |
| Lin, L | 1 |
| Alsweiler, J | 1 |
| Crawford, TJ | 1 |
| Crowther, CA | 1 |
| Wirtz, A | 1 |
| Guarano, A | 1 |
| Capozzi, A | 1 |
| Cristodoro, M | 1 |
| Di Simone, N | 1 |
| Lello, S | 1 |
| Eisenbeis, VB | 1 |
| Qiu, D | 1 |
| Gorka, O | 1 |
| Strotmann, L | 1 |
| Liu, G | 1 |
| Prucker, I | 1 |
| Su, XB | 1 |
| Wilson, MSC | 1 |
| Ritter, K | 1 |
| Loenarz, C | 1 |
| Groß, O | 1 |
| Saiardi, A | 1 |
| Jessen, HJ | 1 |
| Seok, H | 1 |
| Sohn, TS | 1 |
| Oh, TJ | 2 |
| Choi, SH | 2 |
| Okada, H | 1 |
| Tanaka, M | 2 |
| Hasegawa, G | 1 |
| Nakajima, H | 1 |
| Kadono, M | 1 |
| Okada, Y | 4 |
| Hirata, A | 1 |
| Oyamada, H | 1 |
| Yamane, T | 1 |
| Fukui, M | 1 |
| Antonowski, T | 1 |
| Osowski, A | 1 |
| Lahuta, L | 1 |
| Górecki, R | 1 |
| Rynkiewicz, A | 1 |
| Wojtkiewicz, J | 1 |
| Hedrington, MS | 1 |
| Davis, SN | 1 |
| Omori, K | 1 |
| Katakami, N | 3 |
| Arakawa, S | 1 |
| Yamamoto, Y | 1 |
| Ninomiya, H | 1 |
| Takahara, M | 2 |
| Matsuoka, TA | 3 |
| Tsugawa, H | 1 |
| Furuno, M | 1 |
| Bamba, T | 1 |
| Fukusaki, E | 1 |
| Shimomura, I | 2 |
| Takakado, M | 1 |
| Takata, Y | 1 |
| Yamagata, F | 1 |
| Yaguchi, M | 1 |
| Hiasa, G | 1 |
| Sato, S | 2 |
| Funada, JI | 1 |
| Kawazu, S | 1 |
| Osawa, H | 1 |
| Kato, J | 1 |
| Shirakami, Y | 1 |
| Mizutani, T | 1 |
| Kubota, M | 1 |
| Sakai, H | 1 |
| Ibuka, T | 1 |
| Shimizu, M | 1 |
| Nanba, S | 1 |
| Shah, P | 1 |
| Chavda, V | 1 |
| Patel, S | 1 |
| Bhadada, S | 1 |
| Ashraf, GM | 1 |
| Xin, C | 1 |
| Zhao, M | 1 |
| Wang, J | 1 |
| Wang, Z | 1 |
| Wu, GY | 1 |
| Zhang, Q | 1 |
| Wu, JL | 1 |
| Jing, L | 1 |
| Tan, Y | 1 |
| Qiu, TC | 1 |
| Zhao, J | 1 |
| Wittner, L | 1 |
| Satoh, H | 4 |
| Ohira, T | 1 |
| Moriya, C | 1 |
| Inoue, I | 2 |
| Kuribayashi, S | 1 |
| Seino, H | 1 |
| Hirai, H | 1 |
| Hiyoshi, T | 3 |
| Watada, H | 7 |
| Foster, SR | 2 |
| Dilworth, LL | 2 |
| Omoruyi, FO | 2 |
| Thompson, R | 1 |
| Alexander-Lindo, RL | 1 |
| Özturan, A | 1 |
| Arslan, S | 1 |
| Kocaadam, B | 1 |
| Elibol, E | 1 |
| İmamoğlu, İ | 1 |
| Karadağ, MG | 1 |
| Pintaudi, B | 2 |
| Di Vieste, G | 1 |
| Farren, M | 1 |
| Turner, MJ | 1 |
| Daly, S | 1 |
| Kurozumi, A | 1 |
| Chimori, H | 1 |
| Akita, E | 1 |
| Shiraiwa, T | 3 |
| Fujitani, Y | 3 |
| Mita, T | 3 |
| Gosho, M | 3 |
| Koyama, T | 1 |
| Tanaka, A | 1 |
| Yoshida, H | 1 |
| Oyama, JI | 1 |
| Toyoda, S | 1 |
| Sakuma, M | 1 |
| Inoue, T | 2 |
| Otsuka, Y | 1 |
| Node, K | 1 |
| Fujimoto, K | 1 |
| Shibayama, Y | 1 |
| Yamaguchi, E | 1 |
| Honjo, S | 1 |
| Hamasaki, A | 1 |
| Hamamoto, Y | 1 |
| Lambert, C | 1 |
| Cubedo, J | 1 |
| Padró, T | 1 |
| Vilahur, G | 1 |
| López-Bernal, S | 1 |
| Rocha, M | 1 |
| Hernández-Mijares, A | 1 |
| Badimon, L | 1 |
| Goto, H | 1 |
| Fujimoto, S | 3 |
| Takahashi, K | 3 |
| Hirose, T | 4 |
| Ai, M | 2 |
| Nishimura, H | 1 |
| Kuroda, H | 1 |
| Matsubara, T | 1 |
| Ishii, H | 2 |
| Moriwaki, K | 1 |
| Takeuchi, T | 1 |
| Fujimoto, N | 1 |
| Sawai, T | 1 |
| Sato, Y | 3 |
| Kumagai, N | 1 |
| Masuda, J | 1 |
| Nakamori, S | 1 |
| Ishida, M | 1 |
| Yamada, N | 2 |
| Nakamura, M | 1 |
| Sakuma, H | 1 |
| Ito, M | 1 |
| Dohi, K | 1 |
| Santamaria, A | 1 |
| Alibrandi, A | 1 |
| Di Benedetto, A | 2 |
| Corrado, F | 2 |
| Facchinetti, F | 1 |
| D'Anna, R | 2 |
| Parthan, G | 1 |
| Bhansali, S | 1 |
| Kurpad, AV | 1 |
| Walia, R | 1 |
| Bhat, K | 1 |
| Bhansali, A | 1 |
| Miñambres, I | 1 |
| Cuixart, G | 1 |
| Gonçalves, A | 1 |
| Corcoy, R | 1 |
| Gazdzinski, SP | 1 |
| Gaździńska, AP | 1 |
| Orzeł, J | 1 |
| Redlisz-Redlicki, G | 1 |
| Pietruszka, M | 1 |
| Mojkowska, A | 1 |
| Pacho, RA | 1 |
| Wylezol, M | 1 |
| Tsuchiya, S | 1 |
| Sawada, S | 2 |
| Takeda, K | 1 |
| Nakajima, T | 1 |
| Kohata, M | 1 |
| Kurosawa, S | 1 |
| Satake, C | 2 |
| Imai, J | 2 |
| Kikuchi, K | 1 |
| Aiba, S | 1 |
| Katagiri, H | 2 |
| Moelands, SV | 1 |
| Lucassen, PL | 2 |
| Akkermans, RP | 2 |
| De Grauw, WJ | 1 |
| Van de Laar, FA | 2 |
| Yu, JM | 1 |
| Min, KW | 2 |
| Son, HS | 1 |
| Lee, MK | 2 |
| Yoon, KH | 2 |
| Song, YD | 1 |
| Park, JY | 1 |
| Jeong, IK | 1 |
| Cha, BS | 2 |
| Kim, YS | 1 |
| Baik, SH | 2 |
| Kim, IJ | 2 |
| Kim, DM | 2 |
| Kim, SR | 1 |
| Lee, KW | 3 |
| Park, JH | 1 |
| Lee, IK | 2 |
| Park, TS | 3 |
| Park, SW | 1 |
| Kaneko, K | 1 |
| Izumi, T | 1 |
| Yamamoto, J | 1 |
| Asai, Y | 1 |
| Yamada, T | 1 |
| Shi, C | 1 |
| Zhang, R | 1 |
| Bai, R | 2 |
| Liu, D | 2 |
| Wang, Y | 1 |
| Zhang, X | 1 |
| Wang, H | 3 |
| Du, J | 1 |
| Fried, PJ | 1 |
| Pascual-Leone, A | 1 |
| Bolo, NR | 1 |
| Ono, Y | 3 |
| Kameda, H | 1 |
| Cho, KY | 2 |
| Coustan, DR | 1 |
| Ayaori, M | 1 |
| Iwakami, N | 1 |
| Uto-Kondo, H | 1 |
| Sato, H | 1 |
| Sasaki, M | 1 |
| Komatsu, T | 1 |
| Iizuka, M | 1 |
| Takiguchi, S | 1 |
| Yakushiji, E | 1 |
| Nakaya, K | 1 |
| Yogo, M | 1 |
| Ogura, M | 1 |
| Takase, B | 1 |
| Murakami, T | 1 |
| Ikewaki, K | 1 |
| Seo, C | 1 |
| Sakamoto, M | 1 |
| Nishimura, R | 1 |
| Tsujino, D | 1 |
| Ando, K | 1 |
| Morimoto, A | 1 |
| Utsunomiya, K | 1 |
| Yamaguchi, M | 2 |
| Saji, T | 1 |
| Mita, S | 1 |
| Kulmatycki, K | 1 |
| He, YL | 1 |
| Furihata, K | 1 |
| Sekiguchi, K | 1 |
| Otsuki, H | 1 |
| Kosaka, T | 1 |
| Shimomura, F | 1 |
| Kuwahara, Y | 1 |
| Tsukamoto, T | 1 |
| Ohta, A | 1 |
| Ohshige, T | 1 |
| Sakai, K | 1 |
| Tenjin, A | 1 |
| Tsukiyama, S | 1 |
| Terashima, Y | 1 |
| Matsubara, F | 1 |
| Kawata, T | 1 |
| Nagai, Y | 3 |
| Tanaka, Y | 3 |
| Nakamura, A | 2 |
| Nomoto, H | 2 |
| Lee, MY | 1 |
| Choi, DS | 1 |
| Lee, HW | 1 |
| Chung, CH | 2 |
| Kim, DK | 1 |
| Jang, HC | 2 |
| Park, YS | 1 |
| Kwon, HS | 1 |
| Lee, SH | 1 |
| Shin, HK | 1 |
| Sinha, S | 1 |
| Ekka, M | 1 |
| Sharma, U | 1 |
| P, R | 1 |
| Pandey, RM | 1 |
| Jagannathan, NR | 1 |
| Kobayashi, K | 1 |
| Yokoh, H | 1 |
| Takemoto, M | 1 |
| Uchida, D | 1 |
| Kanatsuka, A | 1 |
| Kuribayashi, N | 1 |
| Terano, T | 1 |
| Hashimoto, N | 1 |
| Sakurai, K | 1 |
| Hanaoka, H | 1 |
| Ishikawa, K | 1 |
| Onishi, S | 1 |
| Yokote, K | 1 |
| Jones, RB | 1 |
| Vickers, SP | 1 |
| Cheetham, SC | 1 |
| Headland, KR | 1 |
| Mark, M | 1 |
| Klein, T | 1 |
| Kaneto, H | 2 |
| Kaku, K | 4 |
| Hashiguchi, C | 1 |
| Kawamoto, S | 1 |
| Kasai, T | 1 |
| Nishi, Y | 1 |
| Nagaoka, E | 1 |
| Osonoi, T | 2 |
| Saito, M | 2 |
| Tamasawa, A | 1 |
| Ishida, H | 3 |
| Osonoi, Y | 1 |
| Li, XW | 1 |
| Hao, W | 1 |
| Liu, Y | 1 |
| Yang, JR | 1 |
| Tong, J | 1 |
| Geng, H | 1 |
| Zhang, Z | 2 |
| Zhu, X | 1 |
| Meng, Q | 1 |
| Sun, X | 2 |
| Zhang, M | 2 |
| Qian, R | 1 |
| Sun, L | 2 |
| Liang, Q | 1 |
| Kamoshima, H | 1 |
| Lever, M | 1 |
| McEntyre, CJ | 1 |
| George, PM | 1 |
| Slow, S | 1 |
| Elmslie, JL | 1 |
| Lunt, H | 1 |
| Chambers, ST | 1 |
| Parry-Strong, A | 1 |
| Krebs, JD | 1 |
| Oe, H | 2 |
| Shimada, K | 3 |
| Fukuda, S | 2 |
| Watanabe, K | 3 |
| Takagi, T | 2 |
| Yunoki, K | 1 |
| Hirata, K | 2 |
| Yoshikawa, J | 2 |
| Hariya, N | 1 |
| Mochizuki, K | 1 |
| Inoue, S | 1 |
| Fuchigami, M | 1 |
| Goda, T | 1 |
| Choudhury, SR | 1 |
| Datta, A | 1 |
| Chanda, S | 1 |
| Pathak, AN | 1 |
| Das, S | 1 |
| Raleigh, DP | 1 |
| Jia, W | 1 |
| Xiao, X | 1 |
| Ji, Q | 1 |
| Ahn, KJ | 1 |
| Chuang, LM | 1 |
| Bao, Y | 2 |
| Pang, C | 1 |
| Gao, F | 1 |
| Tu, Y | 1 |
| Yang, J | 1 |
| Croze, ML | 1 |
| Géloën, A | 1 |
| Soulage, CO | 1 |
| Tani, S | 1 |
| Nagao, K | 1 |
| Hirayama, A | 1 |
| Gao, Y | 1 |
| Wu, T | 1 |
| Xu, M | 1 |
| Cai, H | 1 |
| Kasahara, N | 1 |
| Fukase, H | 1 |
| Ohba, Y | 1 |
| Saito, T | 1 |
| Miyata, K | 1 |
| Iida, S | 1 |
| Takano, Y | 1 |
| Ikeda, S | 2 |
| Harigai, M | 1 |
| Terao, K | 1 |
| Son, JW | 1 |
| Woo, JT | 1 |
| Sung, YA | 1 |
| Yoo, SJ | 1 |
| Paul, C | 1 |
| Laganà, AS | 1 |
| Maniglio, P | 1 |
| Triolo, O | 1 |
| Brady, DM | 1 |
| Gao, YF | 1 |
| Zhang, MN | 1 |
| Wang, TX | 1 |
| Wu, TC | 1 |
| Ai, RD | 1 |
| Zhang, ZS | 1 |
| Shi, CH | 1 |
| Wang, L | 1 |
| Wang, YB | 1 |
| Zhang, XY | 1 |
| Yang, Y | 1 |
| Du, JL | 1 |
| Chukwuma, CI | 1 |
| Ibrahim, MA | 1 |
| Islam, MS | 1 |
| Bustamante, J | 1 |
| Lindo, RL | 1 |
| Dash, RP | 1 |
| Babu, RJ | 1 |
| Srinivas, NR | 1 |
| Ihana-Sugiyama, N | 1 |
| Yamamoto-Honda, R | 1 |
| Sugiyama, T | 1 |
| Tsujimoto, T | 1 |
| Kakei, M | 1 |
| Noda, M | 1 |
| Negishi, M | 1 |
| Shimomura, K | 1 |
| Proks, P | 1 |
| Shimomura, Y | 1 |
| Mori, M | 2 |
| Yuan, KL | 1 |
| Shi, XZ | 1 |
| Lu, X | 1 |
| Gao, P | 1 |
| Xu, GW | 1 |
| Heikkilä, O | 1 |
| Lundbom, N | 1 |
| Timonen, M | 1 |
| Groop, PH | 1 |
| Heikkinen, S | 1 |
| Mäkimattila, S | 1 |
| Yao, Y | 1 |
| Shan, F | 1 |
| Bian, J | 1 |
| Chen, F | 1 |
| Wang, M | 1 |
| Ren, G | 1 |
| Haroon, E | 2 |
| Watari, K | 1 |
| Thomas, A | 1 |
| Ajilore, O | 2 |
| Mintz, J | 2 |
| Elderkin-Thompson, V | 1 |
| Darwin, C | 2 |
| Kumaran, S | 2 |
| Kumar, A | 2 |
| Okamoto, T | 1 |
| Okamoto, L | 1 |
| Lisanti, MP | 1 |
| Akishita, M | 1 |
| Kawamori, R | 9 |
| Tajima, N | 5 |
| Iwamoto, Y | 5 |
| Kashiwagi, A | 3 |
| Shimamoto, K | 3 |
| Scheen, AJ | 2 |
| Matsumura, M | 1 |
| Monden, T | 1 |
| Miyashita, Y | 2 |
| Kawagoe, Y | 2 |
| Shimizu, H | 2 |
| Nakatani, Y | 1 |
| Domeki, N | 1 |
| Yanagi, K | 1 |
| Kasai, K | 1 |
| Mühlhauser, I | 1 |
| Shen, L | 1 |
| Yao, L | 1 |
| Horie, Y | 3 |
| Hayashi, N | 3 |
| Dugi, K | 2 |
| Takeuchi, M | 1 |
| Abe, M | 2 |
| Okada, K | 1 |
| Maruyama, T | 1 |
| Maruyama, N | 1 |
| Matsumoto, K | 4 |
| Hiki, M | 1 |
| Kiyanagi, T | 1 |
| Fukao, K | 1 |
| Hirose, K | 1 |
| Ohsaka, H | 1 |
| Fukushima, Y | 1 |
| Kume, A | 1 |
| Matsumori, R | 1 |
| Sumiyoshi, K | 1 |
| Miyazaki, T | 1 |
| Ohmura, H | 1 |
| Kurata, T | 1 |
| Miida, T | 1 |
| Daida, H | 1 |
| Kadowaki, T | 1 |
| Nonaka, K | 1 |
| Taniguchi, T | 1 |
| Nishii, M | 1 |
| Arjona Ferreira, JC | 1 |
| Amatruda, JM | 1 |
| Terao, S | 1 |
| Mimori, N | 1 |
| Suzuki, M | 1 |
| Tachibana, H | 1 |
| Nissen, PM | 1 |
| Nebel, C | 1 |
| Oksbjerg, N | 1 |
| Bertram, HC | 1 |
| Fujitaka, K | 1 |
| Otani, H | 1 |
| Jo, F | 1 |
| Jo, H | 1 |
| Nomura, E | 1 |
| Iwasaki, M | 1 |
| Nishikawa, M | 1 |
| Iwasaka, T | 1 |
| Narita, T | 1 |
| Yokoyama, H | 1 |
| Yamashita, R | 1 |
| Sato, T | 1 |
| Hosoba, M | 1 |
| Morii, T | 1 |
| Fujita, H | 1 |
| Tsukiyama, K | 1 |
| Yamada, Y | 3 |
| Seino, Y | 4 |
| Fujita, T | 1 |
| Hiroi, S | 1 |
| Hirayama, M | 1 |
| Inagaki, N | 2 |
| Araki, E | 2 |
| Sarashina, A | 2 |
| Gong, Y | 1 |
| von Eynatten, M | 2 |
| Woerle, HJ | 2 |
| Dugi, KA | 1 |
| Kim, HJ | 2 |
| Park, KS | 1 |
| Lee, SK | 1 |
| Han, KA | 1 |
| Kim, YK | 1 |
| Ku, BJ | 2 |
| Roman-Ramos, R | 1 |
| Almanza-Perez, JC | 1 |
| Fortis-Barrera, A | 1 |
| Angeles-Mejia, S | 1 |
| Banderas-Dorantes, TR | 1 |
| Zamilpa-Alvarez, A | 1 |
| Diaz-Flores, M | 1 |
| Jasso, I | 1 |
| Blancas-Flores, G | 1 |
| Gomez, J | 1 |
| Alarcon-Aguilar, FJ | 1 |
| Kimura, T | 1 |
| Suzuki, J | 1 |
| Ichikawa, M | 1 |
| Imagawa, M | 1 |
| Fujii, M | 1 |
| Zenimaru, Y | 1 |
| Inaba, S | 1 |
| Takahashi, S | 1 |
| Konoshita, T | 1 |
| Miyamori, I | 1 |
| Hong, JH | 1 |
| Jang, HW | 1 |
| Kang, YE | 1 |
| Lee, JH | 1 |
| Kim, KS | 1 |
| Park, KR | 1 |
| Inoue, M | 1 |
| Thiemann, S | 1 |
| Scilipoti, A | 1 |
| Giordano, D | 1 |
| Caruso, C | 1 |
| Cannata, ML | 1 |
| Interdonato, ML | 1 |
| Odaka, H | 5 |
| Katahira, H | 1 |
| Iijima, T | 2 |
| Kitaoka, H | 2 |
| Sera, Y | 1 |
| Abe, Y | 1 |
| Tominaga, T | 1 |
| Ueki, Y | 2 |
| Miyake, S | 2 |
| Yasuda, K | 2 |
| Shimowada, K | 1 |
| Uno, M | 1 |
| Adachi, T | 1 |
| Shihara, N | 1 |
| Suzuki, N | 1 |
| Tamon, A | 1 |
| Nagashima, K | 1 |
| Hosokawa, M | 1 |
| Tsuda, K | 1 |
| Yamada, K | 2 |
| Geissler, A | 1 |
| Fründ, R | 1 |
| Schölmerich, J | 1 |
| Feuerbach, S | 1 |
| Zietz, B | 1 |
| Mori, Y | 2 |
| Kitahara, Y | 2 |
| Miura, K | 2 |
| Nakamura, T | 1 |
| Matsuda, T | 1 |
| Ogawa, H | 1 |
| Takahashi, Y | 1 |
| Sekizuka, K | 1 |
| Koide, H | 1 |
| Kim, JI | 2 |
| Kim, JC | 2 |
| Kang, MJ | 2 |
| Lee, MS | 1 |
| Kim, JJ | 2 |
| Cha, IJ | 2 |
| Yamasaki, Y | 2 |
| Hayaishi-Okano, R | 1 |
| Matsuhisa, M | 2 |
| Kajimoto, Y | 1 |
| Kosugi, K | 1 |
| Hatano, M | 1 |
| Hori, M | 1 |
| Fujisawa, T | 1 |
| Ikegami, H | 1 |
| Inoue, K | 1 |
| Kawabata, Y | 1 |
| Ogihara, T | 1 |
| Nakamura, J | 1 |
| Van de Lisdonk, EH | 1 |
| Rutten, GE | 1 |
| Van Weel, C | 1 |
| Itoh, Y | 1 |
| Jung, TS | 1 |
| Hahm, JR | 1 |
| Jung, JH | 1 |
| Kang, MY | 1 |
| Moon, SW | 1 |
| Kim, HC | 1 |
| Lee, JD | 1 |
| Kim, JH | 2 |
| Kim, DR | 1 |
| Chung, SI | 1 |
| Nayak, B | 1 |
| Xie, P | 1 |
| Yang, Q | 1 |
| Wada, J | 1 |
| Thakur, A | 1 |
| Danesh, FR | 1 |
| Chugh, SS | 1 |
| Kanwar, YS | 1 |
| Oba, K | 1 |
| Suzuki, K | 1 |
| Ouchi, M | 1 |
| Matsumura, N | 1 |
| Suzuki, T | 1 |
| Nakano, H | 1 |
| Yoshida, K | 1 |
| Morinaga, T | 1 |
| Ikeuchi, M | 1 |
| Kinehara, M | 1 |
| Ashida, H | 1 |
| Oh-I, S | 1 |
| Tsuchiya, T | 1 |
| Ohtani, KI | 1 |
| Okada, S | 1 |
| Kurebayashi, S | 1 |
| Kawasumi, M | 1 |
| Satoh, N | 1 |
| Shimatsu, A | 1 |
| Aizawa-Abe, M | 1 |
| Suganami, T | 1 |
| Kuzuya, H | 1 |
| Ogawa, Y | 1 |
| Yoon, SY | 1 |
| Binesh, N | 1 |
| Miller, J | 1 |
| Thomas, MA | 1 |
| Kim, MJ | 1 |
| Yoo, KH | 1 |
| Seo, YT | 1 |
| Ha, BW | 1 |
| Kho, JH | 1 |
| Shin, YG | 1 |
| Yamazaki, K | 1 |
| Yasuda, N | 1 |
| Nagakura, T | 1 |
| Takenaka, O | 1 |
| Clark, R | 1 |
| Saeki, T | 1 |
| Tanaka, I | 1 |
| Aso, Y | 1 |
| Yamamoto, R | 1 |
| Suetsugu, M | 1 |
| Matsumoto, S | 1 |
| Wakabayashi, S | 1 |
| Matsutomo, R | 1 |
| Takebayashi, K | 1 |
| Inukai, T | 1 |
| Kikuchi, F | 1 |
| Kaizu, K | 1 |
| Kawashima, S | 1 |
| Sakamoto, K | 1 |
| Yasuda, T | 1 |
| Kuroda, A | 1 |
| Yamamoto, K | 1 |
| Kasami, R | 1 |
| Merimee, TJ | 1 |
| Misbin, RI | 1 |
| Gold, L | 1 |
| Varma, SD | 1 |
| Richards, RD | 1 |
| Popp-Snijders, C | 1 |
| Lomecky-Janousek, MZ | 1 |
| Schouten, JA | 1 |
| van der Veen, EA | 1 |
| Dayhaw-Barker, P | 1 |
| Cohen, AM | 1 |
| Wald, H | 1 |
| Popovtzer, M | 1 |
| Rosenmann, E | 1 |
| Galasko, GT | 1 |
| Broomfield, SJ | 1 |
| Hooper, NM | 1 |
| Turner, AJ | 1 |
| Larner, J | 8 |
| Hacibekiroğlu, M | 1 |
| Akçay, T | 1 |
| Zawalich, WS | 1 |
| Zawalich, KC | 1 |
| Kelley, GG | 1 |
| Shulman, GI | 1 |
| Suzuki, S | 1 |
| Kawasaki, H | 1 |
| Satoh, Y | 1 |
| Ohtomo, M | 1 |
| Hirai, M | 1 |
| Hirai, A | 1 |
| Hirai, S | 1 |
| Onoda, M | 1 |
| Matsumoto, M | 1 |
| Hinokio, Y | 1 |
| Simmons, D | 1 |
| Ng, LL | 1 |
| Bomford, J | 1 |
| Ostlund, RE | 2 |
| McGill, JB | 1 |
| Herskowitz, I | 1 |
| Kipnis, DM | 1 |
| Santiago, JV | 1 |
| Sherman, WR | 1 |
| Asplin, I | 1 |
| Galasko, G | 1 |
| Ortmeyer, HK | 2 |
| Bodkin, NL | 1 |
| Lilley, K | 1 |
| Hansen, BC | 2 |
| Hirano, F | 1 |
| Tanaka, H | 1 |
| Okamoto, K | 1 |
| Makino, Y | 1 |
| Inaba, M | 2 |
| Nomura, Y | 1 |
| Fukawa, E | 1 |
| Miura, T | 1 |
| Tani, T | 1 |
| Makino, I | 1 |
| Craig, JW | 1 |
| Yoshioka, K | 3 |
| Azukari, K | 2 |
| Yoshida, T | 3 |
| Kondo, M | 2 |
| Ashida, K | 1 |
| Kasamatsu, Y | 1 |
| Yokoo, S | 2 |
| Kawagishi, T | 1 |
| Nishizawa, Y | 1 |
| Taniwaki, H | 1 |
| Tanaka, S | 2 |
| Okuno, Y | 1 |
| Ishimura, E | 1 |
| Emoto, M | 1 |
| Morii, H | 1 |
| Yano, M | 1 |
| Yamaguchi, Y | 1 |
| Akazawa, S | 1 |
| Tominaga, Y | 1 |
| Bando, Y | 1 |
| Ushiogi, Y | 1 |
| Toya, D | 1 |
| Tanaka, N | 1 |
| Fujisawa, M | 1 |
| Kato, S | 1 |
| Nishimura, M | 1 |
| Mizuno, N | 1 |
| Mukai, E | 1 |
| Kajikawa, M | 1 |
| Ikeda, H | 3 |
| Ihara, Y | 1 |
| Toyokuni, S | 1 |
| Uchida, K | 1 |
| Tanaka, T | 1 |
| Hiai, H | 1 |
| Nestler, JE | 1 |
| Koyama, M | 1 |
| Wada, R | 1 |
| Mizukami, H | 1 |
| Sakuraba, H | 1 |
| Yagihashi, S | 1 |
| Fonteles, MC | 1 |
| Almeida, MQ | 1 |
| Davis, A | 1 |
| Christiansen, M | 1 |
| Horowitz, JF | 1 |
| Klein, S | 1 |
| Hellerstein, MK | 1 |
| Hayakawa, T | 1 |
| Abe, T | 1 |
| Nomura, G | 1 |
| Oki, Y | 1 |
| Okubo, M | 1 |
| Nakanishi, K | 1 |
| Kobayashi, T | 1 |
| Murase, T | 1 |
| Yoshii, H | 1 |
| Uchino, H | 1 |
| Ohmura, C | 1 |
| Takagi, M | 1 |
| Sumitani, S | 1 |
| Kouhara, H | 1 |
| Kasayama, S | 1 |
| Kouzuma, T | 1 |
| Takahashi, M | 1 |
| Endoh, T | 1 |
| Kaneko, R | 1 |
| Ura, N | 1 |
| Watanabe, N | 1 |
| Vichayanrat, A | 1 |
| Ploybutr, S | 1 |
| Tunlakit, M | 1 |
| Watanakejorn, P | 1 |
| Takami, K | 1 |
| Takeda, N | 1 |
| Nakashima, K | 1 |
| Takami, R | 1 |
| Hayashi, M | 1 |
| Ozeki, S | 1 |
| Yamada, A | 1 |
| Kokubo, Y | 1 |
| Sato, M | 1 |
| Kawachi, S | 1 |
| Sasaki, A | 1 |
| Sun, TH | 1 |
| Heimark, DB | 1 |
| Nguygen, T | 1 |
| Nadler, JL | 1 |
| Umeda, F | 1 |
| Hashimoto, T | 1 |
| Nawata, H | 1 |
| Thakkar, JK | 1 |
| Raju, MS | 1 |
| Kennington, AS | 2 |
| Foil, B | 1 |
| Caro, JF | 1 |
| Moller, DE | 1 |
| Moses, AC | 1 |
| Loy, A | 1 |
| Lurie, KG | 1 |
| Ghosh, A | 1 |
| Wilson, JM | 1 |
| MacGregor, LC | 1 |
| Matschinsky, FM | 1 |
| Hill, CR | 1 |
| Craig, J | 1 |
| Bogardus, C | 1 |
| Raz, I | 1 |
| Romero, G | 1 |
| Cai, F | 1 |
| Liang, J | 1 |
| Liao, X | 1 |
| Airey, CM | 1 |
| Price, DE | 1 |
| Kemp, JV | 1 |
| Perkins, CM | 1 |
| Wales, JK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Myoinositol on Serum Asprosin Levels in Pregnant Women[NCT05943158] | 40 participants (Actual) | Interventional | 2021-06-01 | Completed | |||
| Myoinositol Supplementation, Insulin Resistance and Fetal Sonographic Parameters in Gestational Diabetes, Diet Treated: a Prospective, Randomized, Placebo-controlled Study[NCT03763669] | 120 participants (Actual) | Interventional | 2018-11-14 | Completed | |||
| A Randomized Double-blind Study to Evaluate the Effect of Linagliptin on Pancreatic Beta Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy[NCT02097342] | Phase 4 | 30 participants (Anticipated) | Interventional | 2013-12-31 | Recruiting | ||
| An Open-label, Randomized and Crossover Study to Assess the Effect of Co-administration of Vildagliptin and Voglibose on the Steady-state Pharmacokinetics / Pharmacodynamics in Japanese Patients With Type 2 Diabetes[NCT01309698] | Phase 4 | 24 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| A Randomized, Parallel Group, Open-Label, Active-Controlled Study Comparing Acarbose With Voglibose in Patients Who Are Inadequately Controlled With Insulin Glargine Alone or in Combination With Metformin Based on Glycemic Control[NCT00970528] | Phase 4 | 124 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| A Comparison of Premixed and Basal-Bolus Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus With Inadequate Glycaemic Control on Twice-daily Premixed Insulin[NCT01175811] | Phase 4 | 402 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| A Prospective, Randomized and Multi-center Clinical Study to Evaluate Efficacy and Safety of Combination Therapy of Mitiglinide or Voglibose With Long-acting Insulin in Type 2 Diabetic Patients[NCT00663884] | Phase 4 | 167 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Double-blind Phase III Study to Evaluate the Efficacy of BI 1356 5 mg and 10 mg vs. Placebo for 12 Weeks and vs. Voglibose 0.6 mg for 26 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control, Followed by an Extension Study t[NCT00654381] | Phase 3 | 561 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Sitagliptin (MK0431) Phase III Double-blind Comparative Study - Type 2 Diabetes Mellitus -[NCT00411554] | Phase 3 | 319 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan[NCT01263483] | Phase 2/Phase 3 | 230 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Long-term, Open-label Extension Study to Investigate the Long-term Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan[NCT01263509] | Phase 2/Phase 3 | 179 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Effects of Different Doses of Pinitol on Carbohydrate Metabolism Parameters in Healthy Subjects: a Randomized Cross-over Placebo-controlled Study[NCT01738763] | 30 participants (Actual) | Interventional | 2011-07-31 | Completed | |||
| Reduction of Insulin Therapy Under Myo-inositol for the Treatment of Gestational Diabetes Mellitus: a Randomized Multicenter and Prospective Trial. MYO-GDM Study[NCT03875755] | 1,080 participants (Anticipated) | Interventional | 2020-03-04 | Recruiting | |||
| Novel Fiber Effects on Glucose Metabolism and Insulin Sensitivity for Individuals at High Risk for Diabetes: a Randomized, Placebo-controlled, Double-blind, Parallel Group Clinical Trial[NCT00820807] | 60 participants (Anticipated) | Interventional | 2009-01-31 | Terminated (stopped due to Stopped due to a non-safety-related issue with the beverage (test vehicle).) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Least Squares (LS) means are calculated using mixed model repeating measures (MMRM) with the change from baseline in HbA1c at all post baseline measurement as dependent variables, treatment, country, visit and treatment by visit interaction as fixed effects, baseline HbA1c value as a covariate and participant as a random effect. (NCT01175811)
Timeframe: Baseline, 24 weeks
| Intervention | percent HbA1c (Least Squares Mean) |
|---|---|
| Premixed Insulin | -1.05 |
| Basal-Bolus | -1.06 |
Least Squares (LS) means are calculated using mixed model repeating measures (MMRM) with the change from baseline in HbA1c at all post baseline measurement as dependent variables, treatment, country, visit and treatment by visit interaction as fixed effects, baseline HbA1c value as a covariate and participant as a random effect. (NCT01175811)
Timeframe: Baseline, 12 weeks
| Intervention | percent HbA1c (Least Squares Mean) |
|---|---|
| Premixed Insulin | -0.96 |
| Basal-Bolus | -0.96 |
Severe hypoglycemic episode is defined as any event requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. The percentage of participants experiencing a severe hypoglycemic episode is defined as the 100 multiplied by the number of participants experiencing a severe hypoglycemic episode divided by the number of participants exposed to study drug. (NCT01175811)
Timeframe: baseline through 24 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Premixed Insulin | 0.0 |
| Basal-Bolus | 0.0 |
Incidence of hypoglycemic episodes is defined as 100 multiplied by the number of participants experiencing a hypoglycemic episode divided by the number of participants exposed to study drug. Hypoglycemic episodes are defined as an event which is associated with reported signs and symptoms of hypoglycemia, and/or a documented blood glucose (BG) concentration of <= 70 mg/dL (3.9 mmol/L). (NCT01175811)
Timeframe: baseline through 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Premixed Insulin | 54.8 |
| Basal-Bolus | 55.0 |
The rate of hypoglycemic episodes is defined as the mean number of hypoglycemic episodes per 30 days per participant. Hypoglycemic episodes are defined as an event which is associated with reported signs and symptoms of hypoglycemia, and/or a documented blood glucose (BG) concentration of <= 70 mg/dL (3.9 mmol/L). (NCT01175811)
Timeframe: baseline through 24 weeks
| Intervention | hypoglycemic episode/30 days/participant (Mean) |
|---|---|
| Premixed Insulin | 0.468 |
| Basal-Bolus | 0.409 |
Body mass index is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means are calculated using mixed model repeating measures (MMRM) using change from baseline in BMI at all post baseline measurement as dependent variables, treatment, country, visit and treatment by visit interaction as fixed effects, baseline BMI value as a covariate and participants as a random effect. (NCT01175811)
Timeframe: Baseline, 12 weeks, and 24 weeks
| Intervention | kilogram per square meter (kg/m^2) (Least Squares Mean) | |
|---|---|---|
| Change at 12 weeks | Change at 24 weeks | |
| Basal-Bolus | 0.20 | 0.29 |
| Premixed Insulin | 0.26 | 0.31 |
(NCT01175811)
Timeframe: 24 weeks
| Intervention | International Units per kilogram (IU/kg) (Mean) | ||
|---|---|---|---|
| Total Daily Dose | Daily Insulin Dose Basal | Daily Insulin Dose Bolus (prandial) | |
| Basal-Bolus | 0.760 | 0.348 | 0.412 |
| Premixed Insulin | 0.738 | 0.440 | 0.298 |
(NCT01175811)
Timeframe: 24 weeks
| Intervention | International Units (IU) (Mean) | ||
|---|---|---|---|
| Total Daily Dose | Daily Insulin Dose Basal | Daily Insulin Dose Bolus (prandial) | |
| Basal-Bolus | 54.0 | 24.717 | 29.269 |
| Premixed Insulin | 52.9 | 31.539 | 21.385 |
7-point Self-monitored Blood Glucose (SMBG) Profiles are measures of blood glucose taken 7 times a day at the morning pre-meal, morning 2-hours post-meal, midday pre-meal, midday 2-hours post-meal, evening pre-meal, evening 2-hours post-meal, and 0300 hour [3 am]. Each participant took measures on 3 non-consecutive days and the average was calculated for each of the 7 time points. The mean of the 7-point averages was calculated for all the participants at baseline, Weeks 12 and 24. (NCT01175811)
Timeframe: Baseline, 12 weeks, and 24 weeks
| Intervention | milligrams per deciliter (mg/dL) (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Morning Pre-meal (Week 0) (n=195, 201) | Morning Pre-meal (Week 12) (n=187, 191) | Morning Pre-meal (Week 24) (n=177, 186) | Morning 2 hours Post-meal (Week 0) (n=194, 201) | Morning 2 hours Post-meal (Week 12) (n=187, 190) | Morning 2 hours Post-meal (Week 24) (n=176, 184) | Midday Pre-meal (Week 0) (n=195, 200) | Midday Pre-meal (Week 12) (n=187, 190) | Midday Pre-meal (Week 24) (n=177, 186) | Midday 2 hours Post-meal (Week 0) (n=194, 201) | Midday 2 hours Post-meal (Week 12) (n=186, 189) | Midday 2 hours Post-meal (Week 24) (n=175, 184) | Evening Pre-meal (Week 0) (n=195, 200) | Evening Pre-meal (Week 12) (n=187, 190) | Evening Pre-meal (Week 24) (n=177, 186) | Evening 2 hours Post-meal (Week 0) (n=194, 201) | Evening 2 hours Post-meal (Week 12) (n=186, 190) | Evening 2 hours Post-meal (Week 24)(n=176, 185) | 0300 Hours (3 am) (Week 0) (n=185, 193) | 0300 Hours (3 am) (Week 12) (n=177, 185) | 0300 Hours (3 am) (Week 24) (n=171, 179) | |
| Basal-Bolus | 157.7 | 136.5 | 132.4 | 213.6 | 176.5 | 165.8 | 164.9 | 149.4 | 142.1 | 227.5 | 177.2 | 171.1 | 190.0 | 157.6 | 151.1 | 209.9 | 176.2 | 165.6 | 180.0 | 163.6 | 155.8 |
| Premixed Insulin | 155.0 | 141.8 | 137.4 | 207.1 | 179.6 | 169.7 | 160.7 | 142.5 | 139.5 | 219.7 | 162.5 | 161.9 | 186.6 | 148.1 | 145.0 | 204.8 | 177.1 | 172.0 | 175.9 | 150.3 | 145.1 |
The Percentage of participants achieving a haemoglobin A1c (HbA1c) less than or equal (<=) to 6.5% or 7% is defined as 100 multiplied by the number of participants with a HbA1c of the cut-off value (6% or 7%) divided by the number of participants exposed to study drug. Participants with missing HbA1c values at endpoint were treated as not achieving the HbA1c goal. (NCT01175811)
Timeframe: 12 weeks, 24 weeks
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| <=6.5 Percent HbA1c at 12 weeks | <=7.0 Percent HbA1c at 12 weeks | <=6.5 Percent HbA1c at 24 weeks | <=7.0 Percent HbA1c at 24 weeks | |
| Basal-Bolus | 8.9 | 27.7 | 11.9 | 34.2 |
| Premixed Insulin | 6.1 | 26.4 | 9.1 | 29.9 |
Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication (NCT00654381)
Timeframe: 12 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 7.4 |
| Linagliptin 5mg | -12.3 |
| Linagliptin 10 mg | -13.0 |
Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication (NCT00654381)
Timeframe: 26 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Linagliptin 5mg | -5.0 |
| Linagliptin 10 mg | -7.8 |
| Voglibose | 2.0 |
Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication (NCT00654381)
Timeframe: 52 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Linagliptin 5mg | -3.2 |
| Linagliptin 10 mg | -5.9 |
Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication (NCT00654381)
Timeframe: 12 weeks
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Placebo | 0.63 |
| Linagliptin 5mg | -0.24 |
| Linagliptin 10 mg | -0.25 |
Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication (NCT00654381)
Timeframe: 26 weeks
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Linagliptin 5mg | -0.13 |
| Linagliptin 10 mg | -0.19 |
| Voglibose | 0.19 |
The incidence of AEs (Preferred Terms) with a frequency of 5% or more in the patients with type 2 diabetes mellitus who received linagliptin (5 mg or 10 mg) once daily for 52 weeks (NCT00654381)
Timeframe: 52 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Nasopharyngitis | Back pain | Constipation | |
| Linagliptin 10 mg | 81 | 21 | 19 |
| Linagliptin 5mg | 84 | 15 | 12 |
HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 12 (NCT00654381)
Timeframe: 12 weeks
| Intervention | Participants (Number) | ||
|---|---|---|---|
| HbA1c <7.0% | HbA1c <6.5% | HbA1c reduction from baseline ≥0.5% | |
| Linagliptin 10 mg | 56 | 18 | 94 |
| Linagliptin 5mg | 42 | 15 | 91 |
| Placebo | 8 | 0 | 7 |
HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 26 (NCT00654381)
Timeframe: 26 weeks
| Intervention | Participants (Number) | ||
|---|---|---|---|
| HbA1c <7.0% | HbA1c <6.5% | HbA1c reduction from baseline ≥0.5% | |
| Linagliptin 10 mg | 54 | 21 | 84 |
| Linagliptin 5mg | 48 | 15 | 91 |
| Voglibose | 36 | 7 | 61 |
HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 52 (NCT00654381)
Timeframe: 52 weeks
| Intervention | Participants (Number) | ||
|---|---|---|---|
| HbA1c <7.0% | HbA1c <6.5% | HbA1c reduction from baseline ≥0.5% | |
| Linagliptin 10mg | 29 | 10 | 62 |
| Linagliptin 5mg | 38 | 6 | 62 |
Change from baseline at Week 12 is defined as 2-hour postprandial glucose Week 12 minus 2-hour postprandial glucose Week 0. (NCT00411554)
Timeframe: Baseline and Week 12
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Sitagliptin 50 mg QD | -51.0 |
| Voglibose 0.2 mg TID | -32.2 |
Change from baseline at Week 12 is defined as fasting plasma glucose at Week 12 minus fasting plasma glucose at Week 0. (NCT00411554)
Timeframe: Baseline and Week 12
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Sitagliptin 50 mg QD | -19.6 |
| Voglibose 0.2 mg TID | -8.9 |
HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the Week 0 HbA1c percent. (NCT00411554)
Timeframe: Baseline and Week 12
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Sitagliptin 50 mg QD | -0.70 |
| Voglibose 0.2 mg TID | -0.30 |
The change between the value of blood glucose collected at week 12 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12.
| Intervention | mg/dL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 72.4 |
| Alogliptin 12.5 mg QD | 40.9 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 38.7 |
The change between the value of blood glucose collected at week 12 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12.
| Intervention | mg·hr/dL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -4.3 |
| Alogliptin 12.5 mg QD | -74.7 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -76.8 |
The change between the value of C-peptide collected at week 12 or final visit and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12.
| Intervention | ng·hr/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 0.14 |
| Alogliptin 12.5 mg QD | 0.69 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.57 |
The change between the value of fasting C-peptide collected at week 12 or final visit and fasting C-peptide collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 12.
| Intervention | ng/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 0.02 |
| Alogliptin 12.5 mg QD | 0.06 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.10 |
The change between the value of fasting C-peptide collected at week 2 and fasting C-peptide collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 2.
| Intervention | ng/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 0.03 |
| Alogliptin 12.5 mg QD | -0.07 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.01 |
The change between the value of fasting C-peptide collected at week 4 and fasting C-peptide collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 4.
| Intervention | ng/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 0.05 |
| Alogliptin 12.5 mg QD | 0.06 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.01 |
The change between the value of fasting C-peptide collected at week 8 and fasting C-peptide collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 8.
| Intervention | ng/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 0.07 |
| Alogliptin 12.5 mg QD | 0.03 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.01 |
The change between the value of fasting plasma glucose collected at week 12 or final visit and fasting plasma glucose collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 12.
| Intervention | mg/dL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -5.6 |
| Alogliptin 12.5 mg QD | -19.1 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -18.5 |
The change between the value of fasting plasma glucose collected at week 2 and fasting plasma glucose collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 2
| Intervention | mg/dL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -3.5 |
| Alogliptin 12.5 mg QD | -15.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -18.8 |
The change between the value of fasting plasma glucose collected at week 4 and fasting plasma glucose collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 4.
| Intervention | mg/dL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -0.6 |
| Alogliptin 12.5 mg QD | -16.2 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -22.6 |
The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 8.
| Intervention | mg/dL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -2.5 |
| Alogliptin 12.5 mg QD | -20.8 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -21.9 |
The change between the value of glucagons collected at week 12 or final visit and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12
| Intervention | pg·hr/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -0.4 |
| Alogliptin 12.5 mg QD | -19.2 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -20.5 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit and glycosylated hemoglobin collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 12.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Voglibose 0.2 mg TID | 0.04 |
| Alogliptin 12.5 mg QD | -0.96 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.91 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 2.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -0.01 |
| Alogliptin 12.5 mg QD | -0.19 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.21 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 4.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -0.02 |
| Alogliptin 12.5 mg QD | -0.44 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.43 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 8.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -0.01 |
| Alogliptin 12.5 mg QD | -0.74 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.75 |
The change between the value of insulin collected at week 12 or final visit and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12
| Intervention | μU·hr/mL (Mean) |
|---|---|
| Voglibose 0.2 mg TID | -2.47 |
| Alogliptin 12.5 mg QD | 4.62 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 1.50 |
The change between the value of blood glucose collected at week 52 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 39.6 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 39.4 |
The change between the value of blood glucose collected at week 12 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 41.2 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 37.6 |
The change between the value of blood glucose collected at week 24 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 38.0 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 37.1 |
The change between the value of blood glucose collected at week 52 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 39.0 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 40.8 |
The change between the value of blood glucose collected at week 52 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | mg•hr/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -77.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -82.2 |
The change between the value of blood glucose collected at week 12 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | mg•hr/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -73.2 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -76.8 |
The change between the value of blood glucose collected at week 24 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | mg•hr/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -69.0 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -70.4 |
The change between the value of blood glucose collected at week 52 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | mg•hr/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -83.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -83.4 |
The change between the value of C-peptide collected at week 52 or final visit and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | ng•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 1.05 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.80 |
The change between the value of C-peptide collected at week 12 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | ng•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.71 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.71 |
The change between the value of C-peptide collected at week 24 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | ng•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 1.38 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 1.12 |
The change between the value of C-peptide collected at week 52 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | ng•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.96 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 2.18 |
The change between the value of fasting C-peptide collected at week 52 or final visit and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.31 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.29 |
The change between the value of fasting C-peptide collected at week 12 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.10 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.13 |
The change between the value of fasting C-peptide collected at week 16 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 16.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.24 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.21 |
The change between the value of fasting C-peptide collected at week 20 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 20.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.24 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.15 |
The change between the value of fasting C-peptide collected at week 24 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.19 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.14 |
The change between the value of fasting C-peptide collected at week 28 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 28.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.18 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.25 |
The change between the value of fasting C-peptide collected at week 32 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 32.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.47 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.31 |
The change between the value of fasting C-peptide collected at week 36 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 36.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.33 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.38 |
The change between the value of fasting C-peptide collected at week 40 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 40.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.30 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.37 |
The change between the value of fasting C-peptide collected at week 44 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 44.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.08 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.25 |
The change between the value of fasting C-peptide collected at week 48 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 48.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.45 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.38 |
The change between the value of fasting C-peptide collected at week 52 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.80 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.40 |
The change between the value of fasting C-peptide collected at week 8 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 8.
| Intervention | ng/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 0.05 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.11 |
The change between the value of fasting plasma glucose collected at week 52 or final visit and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -17.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -23.3 |
The change between the value of fasting plasma glucose collected at week 12 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -17.1 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -18.8 |
The change between the value of fasting plasma glucose collected at week 16 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 16.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -16.0 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -15.3 |
The change between the value of fasting plasma glucose collected at week 20 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 20.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -15.6 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -15.0 |
The change between the value of fasting plasma glucose collected at week 24 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -13.8 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -15.6 |
The change between the value of fasting plasma glucose collected at week 28 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 28.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -14.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -21.9 |
The change between the value of fasting plasma glucose collected at week 32 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 32.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -17.7 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -20.1 |
The change between the value of fasting plasma glucose collected at week 36 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 36.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -17.3 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -22.6 |
The change between the value of fasting plasma glucose collected at week 40 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 40.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -19.7 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -22.8 |
The change between the value of fasting plasma glucose collected at week 44 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 44.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -21.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -24.4 |
The change between the value of fasting plasma glucose collected at week 48 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 48.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -20.5 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -23.1 |
The change between the value of fasting plasma glucose collected at week 52 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -20.7 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -24.0 |
The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 8.
| Intervention | mg/dL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -18.2 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -20.4 |
The change between the value of glucagons collected at week 52 or final visit and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | pg•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -11.7 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -20.9 |
The change between the value of glucagons collected at week 12 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | pg•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -14.3 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -20.0 |
The change between the value of glucagons collected at week 24 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | pg•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -4.6 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -6.8 |
The change between the value of glucagons collected at week 52 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | pg•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -12.0 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -22.2 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 or final visit and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.81 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.89 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.89 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.96 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 16.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.91 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.96 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 20.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.90 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.89 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.83 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.88 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 28 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 28.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.81 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.89 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 32 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 32.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.80 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.85 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 36 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 36.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.82 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.90 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 40 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 40.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.78 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.92 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 44 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 44.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.88 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.94 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 48 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 48.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.92 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.94 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.95 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.95 |
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 8.
| Intervention | percentage of Glycosylated Hemoglobin (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.69 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | -0.79 |
The change between the value of insulin collected at week 52 or final visit and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).
| Intervention | μU•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -0.61 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.01 |
The change between the value of insulin collected at week 12 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.
| Intervention | μU•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 3.05 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 2.95 |
The change between the value of insulin collected at week 24 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.
| Intervention | μU•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 4.42 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 2.26 |
The change between the value of insulin collected at week 52 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.
| Intervention | μU•hr/mL (Mean) |
|---|---|
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | -1.28 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 0.18 |
A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pre-treatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug, which increases in intensity after the start of dosing. Adverse events data with onset occurring more than 30 days after last dose of study drug (AE start date - last dose date >30) will be listed, but not included in the summary tables below. (NCT01263509)
Timeframe: 52 Weeks.
| Intervention | participants (Number) | ||
|---|---|---|---|
| Serious Adverse Event | Serious Adverse Event Related to Study Drug | Other Adverse Events (Incidence ≥3%) | |
| Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID | 6 | 0 | 85 |
| Alogliptin 25 mg QD and Voglibose 0.2 mg TID | 7 | 1 | 73 |
25 reviews available for inositol and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Dietary Supplements; Female; Humans; Hypert | 2023 |
Alpha Lipoic Acid Efficacy in PCOS Treatment: What Is the Truth?
Topics: Antioxidants; Diabetes Mellitus, Type 2; Female; Humans; Inositol; Insulin; Insulin Resistance; Metf | 2023 |
Health-Promoting Properties of Selected Cyclitols for Metabolic Syndrome and Diabetes.
Topics: Animals; Biomarkers; Blood Glucose; Cyclitols; Diabetes Mellitus, Type 2; Dietary Supplements; Human | 2019 |
Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type | 2019 |
Changes in cerebral metabolites in type 2 diabetes mellitus: A meta-analysis of proton magnetic resonance spectroscopy.
Topics: Aspartic Acid; Brain; Case-Control Studies; Choline; Creatine; Diabetes Mellitus, Type 2; Humans; In | 2017 |
Effect of inositol and its derivatives on diabetes: a systematic review.
Topics: Animals; Blood Glucose; Databases, Factual; Diabetes Mellitus, Type 2; Diabetes, Gestational; Fastin | 2019 |
Effects of inositol on glucose homeostasis: Systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Homeostasis; Humans; Inositol; Insulin Resi | 2019 |
Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
Topics: Acarbose; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diet; Exercise; Fasting; Glucose | 2018 |
Efficacy of voglibose in type 2 diabetes.
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Glucos | 2014 |
Overview of current and upcoming strategies implied for the therapy of type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Developing Countries; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2014 |
Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Inositol; Insulin Resistance; Metabolic Syndrome; Polycys | 2016 |
[alpha-Glucosidase inhibitor, its structure and mechanism of antidiabetic action].
Topics: Acarbose; Animals; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Hum | 2002 |
[Indication and side effect of alpha glucosidase inhibitor].
Topics: Acarbose; Chemical and Drug Induced Liver Injury; Contraindications; Diabetes Mellitus, Type 2; Drug | 2002 |
[Combination therapy with insulin and alpha-glucosidase inhibitor].
Topics: Acarbose; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Thera | 2002 |
[Sulfonylurea and alpha-glucosidase inhibitor].
Topics: Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Gl | 2002 |
[Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
Topics: Acarbose; Animals; Biguanides; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug T | 2002 |
Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glycoside H | 2003 |
[Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
Topics: Acarbose; Cyclohexanes; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Enzyme | 2003 |
[Effects of voglibose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Topics: Animals; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucose Intolerance; | 2005 |
Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glycoside H | 2005 |
Mechanisms of pathogenesis in diabetes mellitus.
Topics: Aldehyde Reductase; Animals; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Histocompatibilit | 1995 |
[Combination therapy with sulfonylurea and alpha-glucosidase inhibitor].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Glycoside | 1997 |
[Alpha-glucosidase inhibitor and insulin sensitizer combination therapy in NIDDM].
Topics: Acarbose; Animals; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycoside Hydrola | 1997 |
[Management of postprandial hyperglycemia].
Topics: Acarbose; Diabetes Mellitus, Type 2; Diet, Diabetic; Exercise Therapy; Humans; Hyperglycemia; Hypogl | 1997 |
D-chiro-inositol in insulin action and insulin resistance-old-fashioned biochemistry still at work.
Topics: Animals; Diabetes Mellitus, Type 2; GTP-Binding Proteins; Humans; Inositol; Inositol Phosphates; Ins | 2001 |
70 trials available for inositol and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Effect of antenatal dietary myo-inositol supplementation on the incidence of gestational diabetes mellitus and fetal outcome: protocol for a double-blind randomised controlled trial.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Dietary Supplements; Female; Humans; Incidence; In | 2022 |
Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure.
Topics: Adiponectin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Glucose; H | 2022 |
Comparison of the Efficacy of Repaglinide Versus the Combination of Mitiglinide and Voglibose on Glycemic Variability in Japanese Patients with Type 2 Diabetes.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Carbamates; Cross-Over Studies; Diabetes Mellitus, Typ | 2020 |
Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus.
Topics: Aged; Biomarkers; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Heart Failure; Hu | 2020 |
Effects of linagliptin vs. voglibose on daily glucose excursions during continuous glucose monitoring of Japanese type 2 diabetes patients (L-CGM): A randomized, open-label, two-arm, parallel comparative trial.
Topics: Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Monitoring; Female; Humans; Hypog | 2017 |
Effects of linagliptin monotherapy compared with voglibose on postprandial lipid profiles in Japanese patients with type 2 diabetes: linagliptin study of effects on postprandial blood glucose (L-STEP) sub-study 1.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; | 2018 |
Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.
Topics: Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV I | 2018 |
Effects of a Carob-Pod-Derived Sweetener on Glucose Metabolism.
Topics: Adolescent; Adult; Aged; Animals; Beverages; Blood Glucose; Body Mass Index; Complement C4a; Diabete | 2018 |
Effects of linagliptin versus voglibose on treatment-related quality of life in patients with type 2 diabetes: sub-analysis of the L-STEP study.
Topics: Activities of Daily Living; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV | 2018 |
Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; H | 2018 |
Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combinatio | 2019 |
Efficacy and safety of sitagliptin added to metformin and insulin compared with voglibose in patients with newly diagnosed type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inositol; Male; Metform | 2019 |
Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Female; H | 2013 |
Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Typ | 2013 |
Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
Topics: Adamantane; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidas | 2013 |
Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fema | 2014 |
Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naïve Japanese patients with type 2 diabetes.
Topics: Aged; Asian People; Blood Glucose; Cross-Over Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Drug | 2013 |
Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal insulin treatment: randomized, parallel, open-label, active-controlled study.
Topics: Acarbose; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glycated Hemoglobin; | 2014 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-i
Topics: 1-Deoxynojirimycin; Aged; alpha-Glucosidases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inh | 2014 |
Efficacy of adding once- and thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibit | 2014 |
Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study.
Topics: Acarbose; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Substitution; Drug Ther | 2014 |
Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose c
Topics: Aged; Blood Glucose; Breakfast; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug | 2014 |
Extreme urinary betaine losses in type 2 diabetes combined with bezafibrate treatment are associated with losses of dimethylglycine and choline but not with increased losses of other osmolytes.
Topics: Adult; Aged; Betaine; Bezafibrate; Choline; Diabetes Mellitus, Type 2; Female; Glycerylphosphorylcho | 2014 |
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Endot | 2014 |
Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Asian People; Blood Glucose; Cardiovascular Diseases; Chemokine | 2014 |
Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily pre
Topics: Acarbose; Aged; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemogl | 2015 |
Differences between Mitiglinide/Voglibose Fixed-dose Combination and Glimepiride in Modifying Low-density Lipoprotein Heterogeneity in Japanese Type-2 Diabetic Patients: A Pilot Study.
Topics: Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glycated He | 2016 |
Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
Topics: Aged; Diabetes Mellitus, Type 2; Diastole; Dipeptidyl-Peptidase IV Inhibitors; Echocardiography; Fem | 2015 |
A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Topics: 1-Deoxynojirimycin; Adult; Benzhydryl Compounds; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Inter | 2016 |
A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglob | 2015 |
[Comparison of therapeutic effects between sitagliptin and voglibose both combined with sensor-augmented insulin pump in newly diagnosed type 2 diabetes].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Glucose Tolerance Test; Glycated Hemoglobin; Huma | 2016 |
Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP).
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Meth | 2016 |
Cross-Over Study Comparing Postprandial Glycemic Increase After Addition of a Fixed-Dose Mitiglinide/Voglibose Combination or a Dipeptidyl Peptidase-4 Inhibitor to Basal Insulin Therapy in Patients with Type 2 Diabetes Mellitus.
Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidases and Tripep | 2017 |
Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inositol; Male; Middle Aged; Pioglit | 2008 |
Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated H | 2008 |
Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.
Topics: Administration, Oral; Analysis of Variance; Diabetes Mellitus, Type 2; Disease Progression; Double-B | 2009 |
Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo.
Topics: Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dou | 2009 |
[Alpha-glucosidase inhibitor for the prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese subjects with impaired glucose tolerance].
Topics: Asian People; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Enzyme Inhibi | 2009 |
Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; H | 2010 |
[Voglibose for the prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese subjects with impaired glucose tolerance].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; In | 2010 |
Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic p
Topics: 1-Deoxynojirimycin; Aged; Coronary Artery Disease; Coronary Disease; Cross-Over Studies; Diabetes Me | 2010 |
Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.
Topics: Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Dr | 2010 |
Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study.
Topics: Adamantane; Asian People; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blin | 2010 |
Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome.
Topics: Adiponectin; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; | 2011 |
[Evidence demonstrating the effect of voglibose for the prevention of type 2 diabetes mellitus: a randomised double-blind trial in Japanese subjects with inpaired glucose tolerance].
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Intolerance; Humans; Hy | 2011 |
Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.
Topics: 1-Deoxynojirimycin; Asian People; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; G | 2012 |
Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibito | 2011 |
Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibito | 2011 |
Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibito | 2011 |
Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibito | 2011 |
Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Dipe | 2012 |
Effects of pinitol on glycemic control, insulin resistance and adipocytokine levels in patients with type 2 diabetes mellitus.
Topics: Adipokines; Adiponectin; Adult; Aged; Blood Glucose; C-Peptide; C-Reactive Protein; Diabetes Mellitu | 2012 |
Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50.
Topics: 1-Deoxynojirimycin; Apolipoprotein A-I; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Melli | 2012 |
Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus.
Topics: Aged; Asian People; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Combinations; | 2012 |
Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Blood Glucose; Body Mass Index; Body Weight; Diabetes | 2013 |
myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Inositol; Pregnancy; Prospective S | 2013 |
Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Female; Glic | 2002 |
Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients.
Topics: Albuminuria; Blood Pressure; Blood Urea Nitrogen; Carotid Arteries; Creatinine; Diabetes Mellitus, T | 2004 |
Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: a randomized controlled study.
Topics: Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; | 2005 |
Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: a randomized controlled study.
Topics: Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; | 2005 |
Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: a randomized controlled study.
Topics: Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; | 2005 |
Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: a randomized controlled study.
Topics: Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; | 2005 |
alpha-Glucosidase inhibitor reduces the progression of carotid intima-media thickness.
Topics: Analysis of Variance; Carotid Arteries; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Glyc | 2005 |
Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study.
Topics: Adiponectin; Administration, Oral; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Female; | 2006 |
Efficacy and adverse effects of nateglinide in early type 2 diabetes. Comparison with voglibose in a cross-over study.
Topics: Aged; alpha-Glucosidases; Appetite; Body Weight; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus | 2006 |
An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients.
Topics: Adult; Biomarkers; Diabetes Mellitus, Type 2; Female; Glycoside Hydrolase Inhibitors; Humans; Hyperg | 2006 |
Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes.
Topics: Adiponectin; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent | 2007 |
Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis.
Topics: Aged; Asian People; Blood Glucose; Case-Control Studies; Demography; Diabetes Mellitus, Type 2; Drug | 2007 |
myo-Inositol and sorbitol in erythrocytes from diabetic patients before and after sorbinil treatment.
Topics: Adult; Aldehyde Reductase; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, T | 1984 |
Relationship between gastric emptying and an alpha-glucosidase inhibitor effect on postprandial hyperglycemia in NIDDM patients.
Topics: Acetaminophen; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Gastric Emptying | 1997 |
Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients.
Topics: Blood Glucose; Cholesterol; Cholesterol, HDL; Data Interpretation, Statistical; Diabetes Mellitus, T | 1998 |
Effect of pinitol treatment on insulin action in subjects with insulin resistance.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Cl | 2000 |
Characteristics of type 2 diabetic patients responding to voglibose administration as an adjunct to sulfonylurea.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Sch | 2001 |
Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients.
Topics: Acarbose; Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Enzyme Inhibito | 2002 |
Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes.
Topics: Abdomen; Adipose Tissue; Adult; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Cholestero | 2002 |
The effect of aldose reductase inhibition on erythrocyte polyols and galactitol accumulation in diabetic patients.
Topics: Aldehyde Reductase; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, | 1989 |
96 other studies available for inositol and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Physiological, Biochemical, and Structural Bioinformatic Analysis of the Multiple Inositol Dehydrogenases from Corynebacterium glutamicum.
Topics: Carbon; Computational Biology; Corynebacterium glutamicum; Diabetes Mellitus, Type 2; Inositol; Mole | 2022 |
Voglibose Regulates the Secretion of GLP-1 Accompanied by Amelioration of Ileal Inflammatory Damage and Endoplasmic Reticulum Stress in Diabetic KKAy Mice.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucose; Ileum; Inositol; Mice | 2022 |
Alternative routes for production of the drug candidate d-chiro-inositol with Corynebacterium glutamicum using endogenous or promiscuous plant enzymes.
Topics: Corynebacterium glutamicum; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Inositol; Oxidoreduc | 2023 |
β-lapachone regulates mammalian inositol pyrophosphate levels in an NQO1- and oxygen-dependent manner.
Topics: Adenosine Triphosphate; Cell Line, Tumor; Diabetes Mellitus, Type 2; Diphosphates; Humans; Hydrogen | 2023 |
Letter: Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inositol; Metformin | 2019 |
Response: Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inositol; Metformin | 2019 |
Identification of Plasma Inositol and Indoxyl Sulfate as Novel Biomarker Candidates for Atherosclerosis in Patients with Type 2 Diabetes. -Findings from Metabolome Analysis Using GC/MS.
Topics: Aged; Atherosclerosis; Biomarkers; Carotid Intima-Media Thickness; Coronary Artery Disease; Diabetes | 2020 |
Simple and non-invasive screening method for diabetes based on myoinositol levels in urine samples collected at home.
Topics: Adult; Aged; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Diagnostic Tests, Routine; Fastin | 2020 |
Alpha-Glucosidase Inhibitor Voglibose Suppresses Azoxymethane-Induced Colonic Preneoplastic Lesions in Diabetic and Obese Mice.
Topics: Animals; Antioxidants; Azoxymethane; Biomarkers; Biopsy; Cell Proliferation; Colonic Neoplasms; Cyto | 2020 |
Promising Anti-stroke Signature of Voglibose: Investigation through In- Silico Molecular Docking and Virtual Screening in In-Vivo Animal Studies.
Topics: Animals; Cerebrovascular Disorders; Computer Simulation; Diabetes Mellitus, Experimental; Diabetes M | 2020 |
Hawthorn polyphenols, D-chiro-inositol, and epigallocatechin gallate exert a synergistic hypoglycemic effect.
Topics: Animals; Catechin; Crataegus; Diabetes Mellitus, Type 2; Glycogen Synthase Kinase 3; Hypoglycemic Ag | 2021 |
Astrocyte-driven plasticity contributes to environment-related changes of hippocampal oscillations.
Topics: Animals; Astrocytes; Diabetes Mellitus, Type 2; Hippocampus; Inositol; Mice; Mice, Knockout | 2017 |
Pancreatic and renal function in streptozotocin-induced type 2 diabetic rats administered combined inositol hexakisphosphate and inositol supplement.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Supplements; Drug Thera | 2017 |
Comment on Farren et al. The Prevention of Gestational Diabetes Mellitus With Antenatal Oral Inositol Supplementation: A Randomized Controlled Trial. Diabetes Care 2017;40:759-763.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Inositol; Nutrition Therapy; Pregn | 2017 |
Response to Comment on Farren et al. The Prevention of Gestational Diabetes Mellitus With Antenatal Oral Inositol Supplementation: A Randomized Controlled Trial. Diabetes Care 2017;40:759-763.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Inositol; Nutrition Therapy; Pregn | 2017 |
Comparison of the effects of linagliptin and voglibose on endothelial function in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, pilot study (EFFORT).
Topics: Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Endothel | 2018 |
Effect of Sitagliptin on Coronary Flow Reserve Assessed by Magnetic Resonance Imaging in Type 2 Diabetic Patients With Coronary Artery Disease.
Topics: Aged; Coronary Artery Disease; Coronary Circulation; Diabetes Complications; Diabetes Mellitus, Type | 2018 |
Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Dietary Supplements; Female; Fetal Growth R | 2018 |
Intragastric balloon therapy leads to normalization of brain magnetic resonance spectroscopic markers of diabetes in morbidly obese patients.
Topics: Adipose Tissue; Body Mass Index; Body Weight; Brain; Creatine; Diabetes Mellitus, Type 2; Female; Ga | 2018 |
Eruptive xanthomas in a patient with soft-drink diabetic ketosis and apolipoprotein E4/2.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adolescent; Apolipoprotein E2; Apolipoprotein E4; Carbonated B | 2019 |
Enhancement of postprandial endogenous insulin secretion rather than exogenous insulin injection ameliorated insulin antibody-induced unstable diabetes: a case report.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Gl | 2019 |
Diabetes and the link between neuroplasticity and glutamate in the aging human motor cortex.
Topics: Aged; Aged, 80 and over; Aging; Aspartic Acid; Creatine; Diabetes Mellitus, Type 2; Female; Glucose; | 2019 |
Can a dietary supplement prevent gestational diabetes mellitus?
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Inositol; Pregnancy | 2013 |
Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study.
Topics: Aged; Asian People; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Combinations; Fe | 2013 |
The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Breakfast; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Combinations; Fa | 2014 |
Assessment of changes in brain metabolites in Indian patients with type-2 diabetes mellitus using proton magnetic resonance spectroscopy.
Topics: Aspartic Acid; Brain Chemistry; Choline; Creatinine; Diabetes Mellitus, Type 2; Glucose; Glutamic Ac | 2014 |
Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Hypoglycemi | 2014 |
Influence of an antidiabetic drug on biomechanical and histological parameters around implants in type 2 diabetic rats.
Topics: Alveolar Process; Animals; Biomechanical Phenomena; Dental Implants; Dental Stress Analysis; Diabete | 2014 |
[Effect of sequoyitol on expression of NOX4 and eNOS in aortas of type 2 diabetic rats].
Topics: Animals; Aorta; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2014 |
Brain metabolite alterations demonstrated by proton magnetic resonance spectroscopy in diabetic patients with retinopathy.
Topics: Adult; Aspartic Acid; Brain; Case-Control Studies; Choline; Corpus Striatum; Diabetes Mellitus, Type | 2014 |
General amyloid inhibitors? A critical examination of the inhibition of IAPP amyloid formation by inositol stereoisomers.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid; Diabetes Mellitus, Type 2; Inositol; Islet Amyloid | 2014 |
[Fixed-dose combination].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Inositol; Isoindo | 2015 |
Abnormalities in myo-inositol metabolism associated with type 2 diabetes in mice fed a high-fat diet: benefits of a dietary myo-inositol supplementation.
Topics: Adipokines; Adipose Tissue, White; Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Dietary Suppl | 2015 |
Effects of D-Pinitol on Insulin Resistance through the PI3K/Akt Signaling Pathway in Type 2 Diabetes Mellitus Rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Fabaceae; Glucose Tolerance Test; Glycogen Syntha | 2015 |
Hypoglycemic effect of D-chiro-inositol in type 2 diabetes mellitus rats through the PI3K/Akt signaling pathway.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose Transpor | 2016 |
Myo-inositol inhibits intestinal glucose absorption and promotes muscle glucose uptake: a dual approach study.
Topics: Administration, Oral; Animals; Biological Transport; Blood Glucose; Carbohydrate Metabolism; Diabete | 2016 |
The effect of combined inositol hexakisphosphate and inositol supplement in streptozotocin-induced type 2 diabetic rats.
Topics: Amylases; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 2016 |
Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Acarbose; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Age | 2018 |
[Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics].
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Biomarkers; Chromatography, Gas; Creatinine; Deoxyguanosin | 2007 |
Risk for metabolic syndrome predisposes to alterations in the thalamic metabolism.
Topics: Adult; Anthropometry; Aspartic Acid; Blood Glucose; Choline; Creatine; Diabetes Mellitus, Type 2; Hu | 2008 |
D-chiro-inositol-enriched tartary buckwheat bran extract lowers the blood glucose level in KK-Ay mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fiber; Disease Models, Animal; Fagopyrum; | 2008 |
Prefrontal myo-inositol concentration and visuospatial functioning among diabetic depressed patients.
Topics: Aged; Cognition Disorders; Depressive Disorder, Major; Diabetes Mellitus, Type 2; Female; Humans; In | 2009 |
Voglibose for prevention of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Inositol; Life Style; P | 2009 |
Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
Topics: Acarbose; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glycoside Hydro | 2009 |
Voglibose for prevention of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Inositol | 2009 |
Voglibose for prevention of type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Glycated Hemoglobin; Humans; Hypoglyc | 2009 |
Metabolomics reveals relationship between plasma inositols and birth weight: possible markers for fetal programming of type 2 diabetes.
Topics: Animals; Biomarkers; Birth Weight; Diabetes Mellitus, Type 2; Female; Fetal Growth Retardation; Gas | 2011 |
Antioxidant and anti-inflammatory effects of a hypoglycemic fraction from Cucurbita ficifolia Bouché in streptozotocin-induced diabetes mice.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Blood Glucose; Cucurbita; Cytokines; Diabetes Melli | 2012 |
Urinary chiro- and myo-inositol levels as a biological marker for type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Inositol; | 2012 |
Long-term therapeutic effects of voglibose, a potent intestinal alpha-glucosidase inhibitor, in spontaneous diabetic GK rats.
Topics: Alkaline Phosphatase; Animals; Blood Glucose; Blotting, Northern; Blotting, Western; Body Weight; Di | 2003 |
Alterations of cerebral metabolism in patients with diabetes mellitus studied by proton magnetic resonance spectroscopy.
Topics: Adult; Aspartic Acid; Blood Glucose; Brain; Chlorides; Choline; Creatinine; Diabetes Mellitus, Type | 2003 |
Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading.
Topics: Animals; Area Under Curve; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Disease Models, A | 2004 |
Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms.
Topics: Acarbose; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fem | 2005 |
Suppression of body weight gain preserves acute insulin response to glucose in the portal vein of spontaneously type 2 diabetic rats with visceral obesity.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Glucose Tole | 2005 |
Determination of urinary Myo-/chiro-inositol ratios from Korean diabetes patients.
Topics: Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Inositol; Insulin | 2005 |
Modulation of renal-specific oxidoreductase/myo-inositol oxygenase by high-glucose ambience.
Topics: Animals; Blood Glucose; Blotting, Northern; Blotting, Western; Cells, Cultured; Diabetes Mellitus, T | 2005 |
Repeated episodes of paralytic ileus in an elderly diabetic patient treated with voglibose.
Topics: Aged; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inosit | 2006 |
Genetic modification of Bacillus subtilis for production of D-chiro-inositol, an investigational drug candidate for treatment of type 2 diabetes and polycystic ovary syndrome.
Topics: Bacillus subtilis; Base Sequence; Biotransformation; Chromatography, High Pressure Liquid; Diabetes | 2006 |
Pinitol from soybeans reduces postprandial blood glucose in patients with type 2 diabetes mellitus.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Female; Food; Glyc | 2006 |
Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Brain Chemistry; Choline; Creatine; Depressive Disord | 2007 |
Effect of pinitol on glucose metabolism and adipocytokines in uncontrolled type 2 diabetes.
Topics: Adiponectin; Aged; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 2007 |
Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice.
Topics: Acarbose; Administration, Oral; Animals; Area Under Curve; Blood Glucose; Carbohydrate Metabolism; D | 2007 |
Acute progression of severe insulin edema accompanied by pericardial and pleural effusion in a patient with type 2 diabetes.
Topics: Administration, Oral; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Progression; Ede | 2008 |
Elevated L-xylulose concentrations in serum: a difference between type I and type II diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucuronates; Glucuronic Acid; | 1984 |
Etiology of cataracts in diabetics.
Topics: Adolescent; Adult; Aldehyde Reductase; Animals; Blood Glucose; Cataract; Child; Child, Preschool; Di | 1984 |
Effect of myo-inositol supplementation on the development of renal pathological changes in the Cohen diabetic (type 2) rat.
Topics: Animals; Blood Glucose; Body Weight; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; | 1995 |
Circulating factors and insulin resistance. I. A novel myoinositol 1,2-cyclic phosphate phosphoglycan insulin antagonist from human plasma is elevated in noninsulin-dependent diabetes mellitus.
Topics: Adipocytes; Adult; Animals; Chromatography, Gel; Cohort Studies; Diabetes Mellitus, Type 2; Female; | 1995 |
The role of plasma, erythrocyte and platelet myo-inositol levels in the development of diabetic microangiopathy.
Topics: Adult; Blood Platelets; Creatinine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic A | 1994 |
Islet phosphoinositide hydrolysis and insulin secretory responses from prediabetic fa/fa ZDF rats.
Topics: Animals; Diabetes Mellitus, Type 2; Heterozygote; Hydrolysis; In Vitro Techniques; Inositol; Inosito | 1995 |
Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes.
Topics: Diabetes Mellitus, Type 2; Female; Gas Chromatography-Mass Spectrometry; Glucose Tolerance Test; Hum | 1994 |
Relationship between myoinositol influx and lipids in diabetic neuropathy.
Topics: Blood Glucose; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; D | 1993 |
D-chiro-inositol metabolism in diabetes mellitus.
Topics: Adult; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gas Chromatography-M | 1993 |
chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Hemodialysis Solutions; Humans; Hydrogen-Ion Concent | 1993 |
Chiroinositol deficiency and insulin resistance. I. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys.
Topics: Analysis of Variance; Animals; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Hyperinsul | 1993 |
Natural course of diabetic peripheral neuropathy in spontaneous-onset diabetic Chinese hamsters.
Topics: Aging; Animals; Cricetinae; Cricetulus; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Electrophy | 1995 |
Urinary myo-inositol-to-chiro-inositol ratios and insulin resistance.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gas Chromatography-Mass Spectrometry; Humans; | 1996 |
Rapid improvement of serum 1,5-anhydroglucitol concentrations after administration of alpha-glucosidase inhibitor.
Topics: Biomarkers; Deoxyglucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glycoside Hydrolase | 1997 |
The efficacy of voglibose on daily glycemic excursions assessed by the "J"-index in non-insulin dependent diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Admini | 1997 |
The efficacy of voglibose on glycemic excursions in non-insulin-treated NIDDM patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; | 1998 |
Three diabetic cases of acute dizziness due to initial administration of voglibose.
Topics: Aged; Aged, 80 and over; Cerebral Infarction; Cerebrovascular Circulation; Diabetes Mellitus, Type 2 | 1998 |
Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fasting; Glucose | 1998 |
Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldehydes; Animals; Blood Glucose; Deoxyguanosine; Diabetes Mellitus, T | 1999 |
Inositolphosphoglycans (IPGs) as mediators of insulin's steroidogenic actions.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inositol; Inositol Phosphat | 1998 |
Inhibition of progressive reduction of islet beta-cell mass in spontaneously diabetic Goto-Kakizaki rats by alpha-glucosidase inhibitor.
Topics: Aging; Animals; Body Weight; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycoside Hydrolase Inhib | 2000 |
Antihyperglycemic effects of 3-O-methyl-D-chiro-inositol and D-chiro-inositol associated with manganese in streptozotocin diabetic rats.
Topics: Animals; Blood Glucose; Chlorides; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Femal | 2000 |
Are there different effects of acarbose and voglibose on serum levels of digoxin in a diabetic patient with congestive heart failure?
Topics: Acarbose; Aged; Aged, 80 and over; Cardiotonic Agents; Diabetes Mellitus, Type 2; Digoxin; Drug Inte | 2000 |
Diabetes mellitus secondary to glycogen storage disease type III.
Topics: Age of Onset; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Disease Progression; Enzyme Inhib | 2000 |
Clinical usefulness of measuring urinary polyol excretion by gas-chromatography/mass-spectrometry in type 2 diabetes to assess polyol pathway activity.
Topics: Adult; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retino | 2001 |
An enzymatic cycling method for the measurement of myo-inositol in biological samples.
Topics: Aged; Bacillus; Biochemistry; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Inositol; Male; NA | 2001 |
Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls.
Topics: Adipose Tissue; Animals; Cell Extracts; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; | 2002 |
Increased inositol phosphate accumulation in platelets from patients with NIDDM.
Topics: Blood Platelets; Cholesterol; Diabetes Mellitus, Type 2; Female; Fibrin; Glycated Hemoglobin; Humans | 1991 |
[3H]myoinositol incorporation into phospholipids in liver microsomes from humans with and without type II diabetes. The lack of synthesis of glycosylphosphatidylinositol, precursor of the insulin mediator inositol phosphate glycan.
Topics: Animals; Calcium; Cytidine Diphosphate Diglycerides; Diabetes Mellitus, Type 2; Gas Chromatography-M | 1990 |
Advances in the diagnosis and pathogenesis of diabetes mellitus and its complications.
Topics: Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dia | 1990 |
Diabetes and the myo-inositol paradox.
Topics: Animals; Aqueous Humor; Blood Glucose; Cornea; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 1990 |
Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus.
Topics: Age Factors; Animals; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dogs; | 1990 |
[Preliminary report of efficacy of diabetic polyneuropathy treated with large dose inositol].
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Inositol; Male; Middle Age | 1990 |